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Cell competition is a phenomenon first reported in Drosophila melanogaster, proven to exist also in 
mammals. It describes the result of a mechanism of fitness comparison undertaken by cells 
inhabiting the same tissue, that leads to the elimination of the weakest cells and, in the physiology, 
to the formation of a homogeneous organ. Over the years, many molecules have been identified that 
are involved in cell competition and among them MYC oncoprotein: from Drosophila to mammals, 
cell populations characterised by higher expression of MYC induce apoptotic death of the 
neighbours, allowing the fittest to acquire an advantage in space occupancy.  
MYC-mediated cell competition has been found to be at work with a dual role in Drosophila 
epithelial tumours: it seems indeed to play tumour suppressive functions at cancer onset and to 
support cancer growth in frankly malignant masses. Clear evidence about its occurrence in human 
cancers is however still missing and, above all, nothing is known about a possible role for cell 
competition in cancer evolution.  
My work defined the presence of markers of MYC-mediated cell competition in primary and 
secondary human carcinomas and demonstrated through experiments in human cancer cell lines that 
MYC modulation is per se sufficient to induce competitive behaviours in both genetically distant 
and identical cells. Noteworthy, MYC under-regulation in the fittest cell line is sufficient to 
undermine its competitive status, suggesting a role for MYC-mediated cell competition in the 
selective growth of tumour clones and, as a consequence, in cancer evolution. In addition, I was 
able to demonstrate a functional cooperation between MYC and p53 in this phenomenon. 
The data obtained in the Drosophila model, where MYC over-expressing and MYC knock-down 
clones have been induced within a growing tumour, suggest that MYC-mediated cell competition is 
normally at work in these malignant cells, and it shapes cancer evolution through the elimination of 
the less fit cells (with lower levels of MYC) and the expansion of the most performant ones (with 
higher levels of MYC), demonstrating an evolutionary role played in defining the composition and 
the size of the final mass.  
Altogether, my results show that MYC-mediated cell competition plays a role in the selection of the 
most performant cells within the tumour and represents an important step towards the understanding 
of the evolutionary mechanisms underlying tumourigenesis, defining for the first time the amazing 
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The evolutionary transition from the unicellular to a multicellular organisation led the 
organisms to acquire several benefits coming from increased complexity, functional 
specialisation of cells and increased size. Many requirements for multicellular 
organisation, such as cell adhesion, cell-cell communication and coordination and 
programmed cell death (PCD), have been developed in time and finely tuned through 
regulatory circuits. Multicellularity is characterised by cooperation among cells for the 
development, maintenance and reproduction of the organism. Complex multicellularity and 
cooperation underlying it have evolved independently multiple times [1].  
Cells are carefully programmed to collaborate in the creation and maintenance of the 
diverse tissues, that make possible organism survival. 
The maintenance of complexity depends on a multitude of strategies and involves wound 
repair and replacement of cells that have suffered attrition after extended periods of life. 
Breakdown of this equilibrium can lead cells to escape from developmental constraints, 
resulting in uncontrolled proliferation and altered behaviour [2]. 
Such changes make the cells incompatible with the assigned roles in structure and 
physiology, as cells no longer obey the rules that drive normal tissue construction and 
maintenance, and undergo various diseases, among which cancer.  
Despite the extraordinary safeguard mechanisms adopted by the organism to prevent their 
appearance, cancer cells seem to have just one aim: making copies of themselves [3]. 
Cancer figures among the leading causes of morbidity and mortality worldwide (second in 
2013), with approximately 14.1 million new cases and 8.1 million cancer-related deaths 
reported in the World Cancer Report 2014. The number of new cases is expected to rise 
over the next two decades. 
Among men, the 5 most common sites of cancer incidence site reported in 2014 were lung, 
prostate, colorectum, stomach and liver; among women the 5 most common sites were 
breast, colorectum, cervix, lung, and stomach [4].  
The heterogeneity and complexity of cancer led to the accepted notion that it represents a 
large group of different diseases involving dynamic changes in the genome. 
It is now widely accepted that it results from the clonal accumulation and cooperation of 
various genetic and epigenetic lesions causing the progressive transformation of normal 
somatic cells into malignant derivatives which can grow, invade and migrate 
uncontrollably. 
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Two general classes of genes are typically affected in cancer cells: oncogenes and tumour 
suppressor genes (TSGs).  
The first are aberrantly activated and represent dominant gain of function (GOF) mutations 
of genes (proto-oncogenes) generally involved in growth and division promotion and 
protection against PCD.  
TSGs are inactivated in cancer cells, resulting in loss of normal cellular functions such as 
accurate DNA damage repair, control over the cell cycle, cell polarity and adhesion within 
tissues [3]. 
Tumour is a cell disease, and all tissues are composed of cells and cell products, so 
virtually cancer can arise in any tissue, but those of epithelial origin, called carcinomas, are 
the most frequent form, representing about 90% of all human malignant tumours. These 
tumours are responsible for more than 80% of the cancer-related deaths in the western 
world.  
 
Moreover, tumours are capable to move within the human body: in many patients, multiple 
secondary tumours are discovered even distant from the primary site as a consequence of 
the tendency of cancer cells to spread throughout the body and establish new malignant 
colonies. 
 
The first carcinogenic events generally lead to local hyperplasia with possible consequent 
formation of metaplasia and dysplasia. From this stage the lesion can evolve in an in situ 
carcinoma, which already exhibits strong alterations in cell physiology and behaviour, such 
as loss of differentiation, loss of apical-basal cell polarity and loss of tissue organisation, 
but the lesion is still confined within a specialised type of extracellular matrix (ECM), the 
basement membrane (or basal lamina), an acellular sheet that separates epithelial cells 
from the underlying layer of supporting connective tissue, the stroma. 
At this stage, tumour-induced angiogenesis can also be observed, with neo-vascularisation 
of the neoplastic mass. 
Finally, the tumour becomes invasive when basement membrane degradation occurs and 
cells disseminate to the neighbouring tissues. These cells can eventually intravasate into 
lymph or blood vessels, allowing their passive transport to distant organs. 
At secondary sites, carcinoma cells can extravasate seeding micrometastases that in 
some cases will form secondary lesions, the final step of this sequence of events often 
termed invasion-metastasis cascade [3].  
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Figure 1.1: Epithelial tumour progression and evolution [5]. 
 
 
1.1. THE HALLMARKS OF CANCER 
 
Cancer research has generated a rich body of evidence, revealing carcinogenesis as a 
multistep process, in which each step enables the cell to collect genetic alterations that, at 
the end, drive the transformation of normal human cells into malignant derivatives.   
The number of cancer-associated genes identified has surpassed the original prediction of 
the gene mutation  theory, according to which only a limited number of key cancer genes 
was thought to be responsible for cancer onset. In order to categorise all cancer-related 
mechanisms, to understand the common biological basis for the huge number of gene 
mutations involved and to reconcile the differences between theoretical prediction and 
clinical fact, various biological capabilities and enabling characteristics of cancer, shown 
to facilitate tumour growth and metastasis, have been summarised in eight hallmarks [6]. 
As tumour development proceeds via a process formally analogous to Darwinian evolution 
[7], the succession of genetic changes, eventually conferring some advantages, leads to the 
progressive conversion of normal human cells into cancer cells. 
There are more than 100 distinct types of cancers and several subtypes of tumours can be 
found within specific organs. But, despite this remarkable diversity, it is possible to 
identify essential physiologic alterations acquired by cells in order to progress towards 
malignancy [8]. 
Hanahan and Weinberg proposed eight common traits of cancer, also known as the 
hallmarks of cancer: sustaining proliferative signals, evading growth suppressors, resisting 
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cell death, enabling replicative immortality, inducing angiogenesis and activating invasion 
and metastasis [8]. 
The hallmarks of cancer, shared by most human tumours, constitute an organising principle 
that provides a logical framework for understanding the remarkable diversity of neoplastic 
diseases. 
              
 
Figure 1.2: The six Hallmarks of cancer [8] proposed by Hanahan and Weinberg in 2000. 
 
Self-Sufficiency in Growth Signals  
The main feature of cancer is abnormal proliferation. No type of normal cells can 
proliferate without mitogenic growth signals (GS) transmitted by transmembrane receptors, 
allowing cells to move from a quiescent state into an active proliferation state characterised 
by stimulating growth, cell cycle entry and cell division. 
Tumour cells generate many of their own growth signals, by reducing dependence from 
their normal tissue microenvironment. In fact, many cancer cells can acquire the ability to 
synthesise growth factors to which they are responsive, creating a positive feedback 
signalling loop often termed autocrine stimulation [9]. Cancer cells become independent 
through constitutive activation of components involved in proliferation, followed by 
oncogene deregulation. This is probably best exemplified by the Ras/MAPK (Mitogen 
Activated Protein Kinase) signalling cascade, as activating mutations of its members are 
found in a significant percentage of human cancers: as an example, RAS proteins are 
present in structurally altered forms, which in turn activate mitogenic proteins, such as 
MYC [10]. 
	  	   7	  
Of note, growth deregulation is carried out by both cancer cells and normal tissue 
surrounding the tumour mass [8] [9]. 
 
Insensitivity to Anti-Growth Signals  
Tissue homeostasis is also maintained by powerful anti-proliferative programmes that 
cancer cells need to modify for proliferation to occur. 
Anti-proliferative signals include either soluble growth inhibitors and immobilised 
inhibitors embedded in the extracellular matrix and on the surfaces of nearby cells. 
Anti-growth signals block proliferation using two strategies: force cells to enter G0 phase 
or a post-mitotic state, usually associated with the acquisition of specific differentiation-
associated traits. Relief of proliferation inhibition is generally obtained through a LOF of 
TSGs; inactivating mutations of these genes are a common feature of all tumours. 
Inhibition of terminal differentiation, allowing the cells to turn to a fully proliferative 
phenotype, is rather achieved through oncogene activation [8] [9]. 
 
Evading Apoptosis  
Further to the over-expressed pro-growth proteins and the insensitivity to the anti-growth 
signals, the ability of the tumour cell population to expand is strongly determined by its 
capacity to evade PCD. 
The apoptotic programme is present in latent forms in all cell types. Once activated by 
several physiologic signals as chemical and mechanical stresses, hyper-proliferation, 
elevated levels of oncogene signalling and DNA damage, PCD, composed by a series of 
steps, is achieved in a span of 30-120 minutes: cellular membranes are disrupted, the 
cytoplasmic and nuclear structures are broken, the cytosol is extruded, the chromosomes 
are degraded and the nucleus is fragmented, while the remaining cell corpse is engulfed by 
nearby cells and disappears within 24 hours.  
The apoptotic machinery can be broadly divided into two classes of components: sensors, 
which recognise pro-apoptotic signals and induce the activation of effectors, which 
respond by releasing in the cytosol the mitochondrial cytochrome C, a potent catalyst of 
apoptosis. 
The way most tumour cells use to evade apoptosis is based on the increased expression of 
anti-apoptotic proteins as Bcl-2, and the inactivation of pro-apoptotic genes through which 
p53 is a well-known example. The p53 tumour suppressor protein can enable apoptosis by 
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upregulating pro-apoptotic Bax in response to DNA damage, so stimulating mitochondria 
to release Cytochrome C [8] [9]. 
 
Limitless Replicative Potential 
Although tumour cells can acquire autonomy from the growth signals, insensitivity to anti-
growth signals and resistance to apoptosis, these features do not ensure expansive tumour 
growth. Almost all mammalian cells are able to undergo a limited number of growth and 
division cycles before irreversibly entering a non-proliferative status named senescence, as 
they have an intrinsic cell-autonomous programme that limits their multiplication. Work on 
cell cultures demonstrated a finite replicative potential, after which cells stop growing and 
undergo senescence [12]. Senescence can be circumvented in cultured human fibroblasts 
by disabling pRB and p53 tumour suppressor proteins, following which these cells enter a 
crisis state. The crisis output is characterised by massive cell death, karyotypic disarray 
associated with end-to-end chromosome fusions and (occasional) cellular immortalisation.  
Moreover, cell cycle seems to be linked to telomere ends. Each cell division, telomeres 
undergo progressive shortening until they reach a critical length at which proliferation 
stops. 
Telomere maintenance is evident in all types of malignant cells [13]: in most of them the 
telomerase enzyme, a special DNA polymerase which adds hexa-nucleotide repeats onto 
the ends of telomeric DNA, is upregulated [8] [9]. 
 
Sustained Angiogenesis 
Oxygen and nutrients are crucial for cell function and survival, obligating all cells to reside 
within a small distance from a capillary blood vessel. The development of new blood 
vessels - the process named angiogenesis - is transitory and carefully regulated. 
Cells composing an aberrant proliferative lesion initially lack angiogenic abilities, 
curtailing their capability for expansion. To progress to a larger size, incipient neoplasia 
must develop angiogenic ability [8] [9]. 
There are positive and negative counterbalancing signals to regulate angiogenesis. The 
initiating signals are mediated by vascular endothelial growth factors (VEGF) and 
fibroblast growth factors (FGF1/2): first evidence about this was reached when anti-VEGF 
antibodies were used to block VEGF molecules during neovascularisation and growth of 
subcutaneous tumours in mice [8] [9]. 
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Grifoni and colleagues have defined in Drosophila, where the oxygen is conveyed to the 
internal organs through an interconnected tubular network called “tracheal system”, that 
the regulation is significantly analogue to that of mammalian angiogenesis: in an 
epithelial cancer model, Drosophila FGF/FGFR (FGF Receptor), encoded by 
the branchless (bnl) and breathless (btl) genes respectively, carry out the functions of 
VEGF/VEGFR in inducing angiogenesis [14]. 
 
Tissue Invasion and Metastasis 
Invasion and metastasis are exceedingly complex processes, and their genetic and 
biochemical determinants remain not explained at all in their complexity. 
During the development of most types of human cancer, primary tumour masses can 
spread invading adjacent tissues or distal sites, where they may form new colonies. 
Metastases are responsible for the 90% of cancer mortality. The invasive and metastatic 
process is a multistep mechanism. The process begins with local invasion of pioneer cells 
from the primary mass to the nearby surrounding tissues, followed by intravasation of 
cancer cells into blood or lymphatic vessels where they transit till they are stopped. Cancer 
cells can reach the parenchyma of a tissue (through a mechanism termed extravasation) 
followed by the formation of small micromasses, and if the microenvironment features are 
permissive, they may grow into a macroscopic tumour (colonisation). 
To allow cell intravasation, it is important that the epithelial cells change their programmed 
information, acquiring the ability to invade, to resist apoptosis and to disseminate. This 
happens because cells develop a new regulatory programme, named the “epithelial-
mesenchymal transition” (EMT). 
The EMT programme can be transiently or stably activated by cancer cells during invasion 
and metastasis, orchestrated through a set of pleiotropically acting factors. Evidence from 
developmental genetics indicates that contextual signals received from neighbouring cells 
are involved in the activation of these factors. In the invasive and metastatic process, a 
crosstalk between cancer and stromal cells is involved. This observation indicates that the 
phenotype of high-grade malignancies do not arise in a strictly cell-autonomous manner, 
and their behaviour cannot be simply understood through tumour genome analysis. 
Other two mechanisms of invasion have been identified: collective invasion, where cells 
migrate in clusters, and amoeboid invasion in which individual cells slide through existing 
interstices. 
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In some types of cancer, the primary tumour may release systemic suppressor factors that 
render such micro-metastases dormant, as revealed clinically by explosive metastatic 
growth. Other macroscopic metastases may erupt decades after a primary tumour has been 
removed.  
Clinical evidence shows as individual types of carcinoma form metastases only in a limited 
subset of target organs, for a phenomenon called “tissue tropism” or “homing”. The 
reasons for this selectivity are still not completely understood. Substantial progress is 
currently being made to define a metastatic signature of gene expression changes which 
correlate with the establishment of macroscopic metastases in specific tissues. This would 
also help clarify how metastasis-promoting genetic alterations are selected within the 
primary tumour: whether these mutations are also beneficial to primary growth and thus 
are fixed before cells start to disseminate, or whether they are stochastically accumulated 
as “passenger" mutations that only subsequently give an advantage before to be fixed. 
Alternatively, cells may leave the tumour in a partially metastatic-competent condition and 
further evolve once they experience the new environment-associated pressure. Indeed, an 
increasing body of evidence seems to point towards a parallel progression model for 
certain types of carcinomas, according to which mutant cells disseminate relatively early, 
from pre-neoplastic lesions, and undergo genetic diversification and selection within the 
distant target organs, thus showing a rather different genetic profile with respect to the 
primary tumour [8] [9]. 
 
Enabling Characteristics  
When we talk about cancer we have always to consider the acquired functional capabilities 
that allow cancer cells to survive, proliferate and disseminate; these functions are made 
possible by enabling characteristics that drive cells to switch into a cancer state. Most 
prominent is the development of genomic instability, which can generate random 
mutations which allow cancer cells to acquire multiple hallmarks. In fact, despite the 
extraordinary capacity of the genome control systems used to solve DNA defects, during 
the first stages of tumourigenesis cancer cells increase their rate of mutation by increasing 
cell cycle speed.  
Another important feature of cancer cells is the acquisition of an inflammatory state of pre- 
and malignant lesions, driven by the immune defense system, used to promote tumour 
progression.   
	  	   11	  
In fact, evidence shows as tumours are densely infiltrated by cells of either innate and 
adaptive immune system. Paradoxically, the tumour-associated inflammatory response 
enhances tumourigenesis by supplying bio-active molecules to the tumour 
microenvironment, including growth factors that sustain proliferative signalling, survival 
factors that limit cell death, pro-angiogenic factors, extracellular matrix-modifying 
enzymes that facilitate angiogenesis, invasion and metastasis, inducing signals that lead to 
activation of EMT. The surrounding inflammation generates the conditions for the 
formation of a pre-cancerisation field, in which the future tumour cells switch to an active 
state [11].  
 
Emerging Characteristics  
A characteristic which plays an important role in cancer expansion and aggressivity is 
cancer cells’ capacity to reprogramme metabolism. In fact, even in presence of oxygen, 
these cells switch to a less efficient glycolytic metabolism, the so-called Warburg effect. 
The glycolytic afflux can be regulated by oncogenes such as MYC and RAS (as well as a 
hypoxic condition). The significance of this is not fully understood, but an explanation can 
be found in the fact that these cells, following to fitness comparison with wild-type cells, 
may over-proliferate and colonise the great part of the tissue [15]. A second emerging 
hallmark in tumour formation involves mechanisms of immune evasion, as anti-tumour 
immunity creates a significant barrier to tumour formation and progression [11].   
                      
Figure 1.3: The Emerging Hallmarks and Enabling Characteristics [11]  Hanahan and Weinberg added to 
their 2011 review: Hallmarks of Cancer: The Next Generation. 
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1.2. CANCER EVOLUTION 
 
Cancer can be considered as a reiterative process of clonal expansion characterised by 
genetic diversification and clonal selection within the adaptive landscapes of tissue 
ecosystems. The current molecular cancer research is based on the “gene mutation theory” 
based on the evidence that gene aberrations and stepwise gene mutations drive cancer 
progression. While the hallmarks of cancer have been influential as they provided a 
rationale for clinical approach in cancer research, cancer dynamics cannot be lonely 
summarised by isolated and fixed molecular principles [6], as neoplasms are microcosms 
of evolution [7]; in the same way, the laws that rule cancer mutations are highly mutant. 
Within a neoplasm, a mosaic of mutant cells compete for space and resources, evade 
predation by the immune system and cooperate to colonise new organs. 
The idea of cancer as an evolutionary disease is not new. A tumorous mass is a heterogenic 
population in terms of genetics and epigenetics, and obey the Darwinian evolutionary laws. 
Organism-level and gene-level evolution led to achieve general tumour-suppression 
mechanisms and oncogenic vulnerabilities in our genomes through several levels of 
selection: neutral and non-neutral mutations, genetic drift, epigenetics, natural and artificial 
selections, colonisation and dispersion [7]. Mutations modify cell fitness and affect cellular 
fate through genetic drift and Darwinian selection by which the tumour mass can survive 
and expand itself. Cell fitness is shaped by its interactions with cells and other factors in its 
microenvironment, as the reproductive power of species depends on the environment [7]. 
Various forms of mutation have a role in the neoplastic progression. Studies of 
heterogeneity in tumours show that there is extensive cytogenetic, genetic and epigenetic 
variability in cancer cell populations, and the degree of variability can predict progression 
towards malignancy.  
Genetic instability generates genetic heterogeneity, and this point may be recognised as a 
hallmark of cancer. Each clone in each cancer in each patient has a unique genome profile 
[16]. Researchers have shown that the type of environmental insults selects against the 
checkpoints that they trigger, as cells that lose checkpoints can reproduce more quickly 
than non-mutated populations [17].   
Mutation frequency studies and measurements in cell culture calculated the sequence 
mutation rate at 10-6-10-7 per locus per cell generation [18]. The estimation of number of 
mutations necessary to cause cancer is about 3-12 mutations for different forms of cancer 
[19]. But a genetic mutation might not always affect cells, as most of them can be neutral 
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mutations, so the spontaneous rate of somatic mutation is not high enough to generate the 
many mutations needed for neoplastic expansion. To solve this paradox, also known as the 
Loeb paradox, two hypotheses have been proposed: a genetically unstable phenotype 
increasing mutation rate might arise, or clone expansion generates target populations large 
enough to produce the necessary subsequent mutations [20], both resulting in a big 
heterogeneity of clones and cancers. To explain this great heterogeneity, over the decades, 
researchers have developed several theories based on the consideration of the tumour as a 
living organism in continuous interaction with its surrounding environment. 
Two of the most quoted hypotheses are based on the clonal evolution theory and the 
cancer cell plasticity theory. Both theories, strongly connected to each other, explain how 
tumour clones achieve a high degree of cellular, phenotypic and functional heterogeneity.  
Through mechanisms of cellular plasticity cancer cells can acquire functions and roles 
distant from their committed fate that, through typical Darwinian evolutionary 
mechanisms, result in the selection of aggressive clones characterised by high cell fitness 
and clonal expansion. 
 
1.2.1. Clonal Evolution 
As Peter Nowell showed in his work about tumour evolution, cancer is driven by stepwise 
somatic-cell mutations with sequential sub-clonal selection within tissue ecosystem [16].  
Given the strong selective pressure imposed by the microenvironment surrounding cancer 
cells, just a little proportion of mutated cells can undergo neoplastic events that are not 
stalled and aborted. 
In advanced malignancy, because of limited resources, cancer-suppressive mechanisms 
and potent artificial selection in form of drugs, the time used for cancer symptoms to 
emerge is quite long (depending also on the primary location). 
The advanced malignancy growth respects the Gompertzian function [21], according to 
which cancer cells doubling time (1-2 days) is much faster than tumour doubling time 
(around 60-200 days). The Gompertzian growth explains the long time period usually 
required for cancer symptoms to emerge and the time needed to provide a positive 
selection of variant cells able to resist and overgrow. So, natural selection in tumours takes 
place, in the same way as selection in organisms, by competition for space and resources. 
Cancer happens because of the exposure of the cells to genetic instability that could create 
mutations. But mutation rate varies substantially between different genomic regions [22] 
and the mutagenic processes are essentially blind or non-purposeful [23], and clones 
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evolve through the interaction of selectively advantageous driver lesions (gain and/or loss 
of functions), selectively neutral lesions (also known as passenger) and deleterious lesions. 
But mutated cells have an increased mutation rate, the meaning of this is that some of the 
phenotypic silent mutations or the passenger lesions drive other genetic changes allowing 
clonal expansion. The driver mutations give, as in the case of glioblastoma or pancreatic 
cancers, an average fitness advantage of only 0.4 % (using a non-spatial population 
genetics model to quantify the selective advantage provided by driver mutations) [24]. So 
the dynamics of somatic evolution depends on the interaction of mutation rate and clonal 
expansion. 
The model of clonal evolution suggests that a series of clonal expansions grow to dominate 
the neoplasm (for the mechanism of clonal sweeps), until a next mutation is achieved. If or 
when the second mutation occurs, the expansion of both clones is restrained by mutual 
competition (clonal interference). Given the large population size and the high mutation 
rate typical of neoplasms, clonal competition is probably common [26] [27]. 
The scientific community is long debating about the way mutations have to occur to allow 
clonal evolution. The two main theories are based either on the gradualism theory, by 
which lesions accumulate over time in undetected sub-clones that finally appear following 
neoplasm expansion, or on the punctuated equilibrium theory, by which few big mutational 
events generate multiple lesions across the genome.  
The latter theory is most accepted simply because the impossibility, in almost all cancers, 
to find out intermediate clones (in B-cell chronic lymphocytic leukaemia the frequency is 
<0.001%) to prove the gradualism hypothesis.  
However it remains unclear whether sub-clone diversification reflects the impact of driver 
mutations and selective advantage, genetic drift of selectively neutral mutations or 
epigenetic alterations [27]. 
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Figure 1.4: The branched architecture of evolution [28]. Representative pattern for common solid cancer 
evolution: selective pressure allows some mutant subclones to expand and other become extinct or remain 
dormant. Vertical lines represent the selective pressures in different habitats. TX represents therapy. 
 
 
1.2.1.1.  Sub-clonal segregation of mutations and clonal architecture 
Most histopathological evidence supports the classical model of clonal evolution followed 
by sub-clonal dominance and/or selective sweeps. 
The evidence of the complex pattern of sub-clonal segregation of mutations came from a 
large data of deep sequencing and single-cell analysis. By comparing the mutational 
genomes of the sub-clones, it is possible to trace their evolution.  
Evidence of clonal evolution from a common ancestral cancer cell has been found in 
identical twins with a concordant acute leukaemia with metastatic lesions: divergent cancer 
clone genotypes and phenotypes correspond to allopatric (genetic isolation) speciation in 
separate natural habitats [29] (Fig 1.5). 
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Figure 1.5: Prostate topography of cancer subclones [28]. A. Tissue section of prostate to detect genetic 




The level of biodiversity within the sub-clonal structure can be measured, and also, as the 
profile of sub-clones within a neoplasm can be used to determine the molecular clocks 
linked to time events in the history of the neoplasm, it has been shown to be a robust 
biomarker for predicting progression in some cancer diseases.  
 
1.2.2. Cancer Cell Plasticity 
Tissue and organ physiological developmental processes are based on the capacity of the 
stem/progenitor cell pools to activate different pathways allowing them to undergo a 
committed fate. 
The commitment is controlled in a strict way by epigenetic regulators and transcription 
factors that organise the specific gene expression patterns of each lineage. This mechanism 
also occurs by de-differentiation phenomena by which differentiated cells can change their 
normal developmental programme and acquire a new fate, even distant from that of the 
lineage they come from. 
Many studies during the years proved the de-differentiation of committed cells to a 
totipotent stage: after Brigs and Kings in 1952 [30] generated frog tadpoles by 
transplanting the nucleus from the blastula into frog enucleated oocytes, demonstrating the 
possibility for pluripotent cells to acquire a totipotent fate, in 1962 Gurdon and 
collaborators [31] generated Xenopus by transplanting nuclei from intestinal epithelial cells 
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into Xenopus oocytes, showing that committed nuclei may change their somatic fate into a 
germinal fate. 
Strong evidence in mammals came from the cloning of Dolly the sheep [32] [33], where 
Wilmut and collaborators in 1997 proved that changes in cell fate did not involve 
irreversible nuclear changes: the fact that a lamb was derived among others from an 
adult mammary gland cell confirmed that differentiation of that cell did not involve 
irreversible modifications of the genetic material required for development and there were 
changes in gene expression but not in gene sequence, indicating that the developmental 
fate restrictions occurring during normal development can also result from epigenetic 
modifications [34]. 
Cellular plasticity based on epigenetic memory and involving chromatin regulators (e.g. 
Trithorax and Polycomb group Proteins [35] ) is a fundamental trait of normal organ and 
tissue development. 
The de novo progenitor state (acquired progenitor state) is not as stable as expected, and 
cell plasticity is indeed involved in several diseases mainly characterised by abnormal 
cellular reprogramming. 
The plasticity of the very first cells harbouring oncogenic alterations plays an important 
role in cancer development, leading the cell to acquire stem cell proprieties and allowing it, 
in the worst case scenario, to develop a tumour mass. Different types of cells contribute to 
the tumour structures and while the great majority of them are differentiated, there is a 
small percentage of Cancer Stem Cells (CSCs) that are important for replenishing cancer 
mass. The CSC theory considers cancer as any other stem-cell-maintained tissue, as only 
CSCs are able to reform the tumour if injected in a responsive model [36]. So, this theory 
explains how tumour is not only a result of genetic mutations affecting oncogenes and 
TSGs, but it comes from altered cell-fate programmes, where committed cells are able to 
de-differentiate to ensure a cancer stem pool (fig 1.6a). Conventional therapy is known to 
be ineffective at eliminating CSCs, which allow tumour cells to eventually repopulate the 
organ (fig 1.6b); however, targeting CSCs will leave the bulk of the tumour intact. A 
remaining tumour cell could then convert into a CSC, allowing for tumour recurrence and 
metastasis. Combination therapies targeting both CSCs and non-CSCs are likely needed to 
better prevent tumour recurrence and metastasis [37]. 
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Figure 1.6: Plasticity of cancer stem cells [37]. A). The initial tumour is composed of non-cancer stem cells 
(CSCs; yellow) and rare CSCs (red). Non-CSCs within the tumour can mutate in non-CSC (blue). 
Spontaneous conversion of new non-CSC (blue) into a new CSC (green) provides tumour with genetically 
distinct CSCs (red and green) B). Conventional therapy and future therapy. 
 
Evidence of this kind of cell plasticity can be found in haematopoietic tumours, where 
leukaemia stem cells are very similar to myeloid populations with the haematopoietic stem 
cell programme activated [38], and in some epithelial cancers where an embryonic stem 
cell-like (ESC-like) programme can be activated by oncogenes to allow, for intestinal 
cancers, to generate cancer cells from the crypt stem cells.  
Plasticity during tumour development is comparable to normal development, where cell 
fate is programmed in early progenitors, but the final effects of these programming events 
are only evident in differentiated cells. 
 
1.3. EPIGENETICS AND CANCER 
 
In the study of cancer and its mutations it cannot be excluded an amount of non-genetic 
mechanisms that drive positive selection during growth, including signalling plasticity, 
quiescence and epigenetic changes [39]. Global changes in the epigenetic landscape are a 
hallmark of cancer: its disruption can lead to altered gene function and malignant 
transformation [39]. Epigenetics describes the study of heritable and non-heritable changes 
in gene expression that occur independently of changes in primary DNA sequence, 
involving the organisation of genome and chromatin structure and influencing the ability of 
genes to be activated or silenced. The sum of these modifications, collectively referred to 
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as epigenome, provides a mechanism for cellular diversity by regulating how genetic 
information can be accessed by the cellular machinery [40]. The majority of these 
modifications are maintained through cycles of cell division allowing cells that share the 
same genetic information to have the same epigenetic organisation. The rate of epigenetic 
changes, also known as epi-mutations, has been estimated to be higher than the genetic 
changes, and could thus be a major determinant of clonal evolution [41]. As epi-mutations 
affect cell phenotype, they can also underlie natural selection. 
Failure of the epigenome machinery can result in activation or inhibition of various 
signalling pathways, leading to several diseases such as cancer [42] [43] where they play 
important roles from the early stages to progression in conjunction with genetic mutations 
or deletions. In addition to tumour suppressors’ inactivation and oncogenes’ activation, 
coming from a general genomic instability, they could serve as a second hit required for 
cancer initiation according to the Knudson’s “two hits model”. Among the types of 
epigenome aberrations found in cancers, the hypo-methylation of CpG islands in 
promoters, repetitive elements, introns and genes play a significant role. A low rate of 
methylation in transposons, e.g., increases genome instability induced by their 
translocation or rearrangements or leading to gene activation [44]. In contrast, hyper-
methylation of TSGs can lead to gene inactivation, such as it happens to BRCA1 and p16 
[45]. 
 
                     
Figure 1.7: Epigenetic gene silencing (B) and activation (A) [46]. Two possible mechanisms by which 
epigenetic modifications can lead to cancer. 
 
Other modifications include changes in histone epigenetics, deregulation of miRNA, the 
modified nucleosome positioning system and the stem cell fate epigenetics-induced 
modifications.  
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The CSCs model suggests that epigenetic changes, which occur in normal stem or 
progenitor cells, are the earliest events in cancer initiation [47]. Since epigenetic 
mechanisms are central to the maintenance of stem cell identity and epigenetic changes 
drive the early stages of cancer progression, these same changes may modify the fate of 
cells, inducing de-differentiation, one of the most common events in tumourigenesis.  
For example, silencing of genes involved in the maintenance of stem/progenitor cell state, 
such p16 or APC, early markers of colon cancer, is induced by DNA hyper-methylation 
[48]; the Polycomb Complex Group proteins (PcG), involved in the silencing of 
developmental regulators in ES cells, are upregulated in various forms of cancer through 
hyper-methylation of the Polycomb repressive marks, suggesting another link between 
cancer and epigenetic regulations [49].  
 
1.4. MODELLING CANCER IN DROSOPHILA 
 
Cellular and animal models are contributing to the acquisition of knowledge on the genetic 
basis of cancer, and among all models Drosophila melanogaster, the fruit fly, has been 
largely used to investigate the mechanisms underlying the behaviour of cancer cells 
growing in heterotypic backgrounds: mutant cells growing in heterotypic contexts can 
mimic the typical clonal formation of a tumour and allow researchers to study the 
interactions with adjacent populations of cells bearing different genetic arrangements [50].  
Drosophila and human epithelia are comparable in structure and composition and more 
than 50 Drosophila genes have been identified in the control of proliferation of cells in a 
variety of tissues including embryonic tissues, nervous system, imaginal discs, larval 
hematopoietic and adult gonadal tissues [51]. Genes and pathways controlling proliferation 
and growth in Drosophila are largely conserved in humans, therefore the study of 
Drosophila TSGs and proto-oncogenes has produced a strong contribution to a better 
understanding of cancer biology in humans. Nowadays Drosophila represents an 
invaluable model in cancer research, as the powerful and sophisticated genetic tools 
available allow to study the clonal effects of multiple genetic manipulations on populations 
of cells which are embedded in and interact with the surrounding normal tissue. 
The first tumourous mutation was described in the 60’s by Elizabeth Gateff: this mutation 
affected a locus named lethal giant larvae, lgl, that acted in a recessive manner, mimicking 
a TSG. In the following years, thanks to the development and improvement of genetic and 
molecular tools to allow wide genetic screens, several other TSGs were identified in 
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Drosophila that caused uncontrolled proliferation leading to tumour growth, and proved to 
be functionally conserved in mammals and also altered in human cancers.  
 
1.4.1. lethal giant larvae is a TSG 
Conventionally only the genes that cause over-proliferation in Drosophila can be defined 
as fly TSGs and they are classified into two main categories [52]: 
- Hyperplastic TSGs are those genes that when mutated display extensive over-
proliferation of the imaginal epithelia without affecting cell monolayer 
organisation, and mutant tissue is able to differentiate into rudimental adult organs.  
- Neoplastic TSGs are classified as genes that, when mutated in the imaginal 
epithelia, cause over-proliferation accompanied by loss of apical-basal cell polarity; 
moreover mutant tissue never differentiate. When transplanted into adult wild-type 
hosts, the mutant tissue from neoplastic TSGs is able to overgrowth, spread and kill 
the host [53]. Among the neoplastic tumour suppressors so far identified, lethal 
giant larvae, discs large (dlg) and scribble (scrib) are of particular interest as they 
encode conserved proteins involved in the establishment and maintenance of 
epithelial apical-basal polarity as well as in proliferation control. The regulation of 
epithelial cell polarity is a crucial issue in cancer biology as its loss is a key feature 
of carcinomas [54], [55].	  	  
1.4.2. lethal giant larvae and Cell Polarity 
Most cell types are polarised in space with distinct structural orientations, following Planar 
Cell Polarity (PCP) and Apical-Basal Polarity (A/B) established by distinct protein 
localisation patterns that allow cells to perform specialised functions. Correct 
establishment and maintenance of cell polarity is required for the development and 
homeostasis of all metazoans and disruption of cell polarity is one of the early events in 
carcinogenesis and represents a hallmark of cancer [56].  
While PCP describes the coordinated alignment of cells across the tissue plane [57], the 
A/B polarity is defined as the existence of cells which display an upper, apical pole and a 
lower, basal pole (fig 1.17), essential for adhesion, communication, morphogenetic 
properties of epithelia and to signal between the interior of the organism and the external 
environment. Loss of A/B cell polarity is a specific feature of the lgl LOF phenotype. 
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The Lgl/Scrib/Dlg complex establishes and maintains the basal-lateral cell domain, 
antagonising the activity of two other protein complexes: Crumbs/Stardust/PATJ (apical 
domain) and Bazooka(Par3)/Par6/aPKC (sub-apical domain).  
 
                              
 
Figure 1.8: Schematic representation of an epithelium showing an A) apical-basal polarity and B) planar 
Polarity. C) their appearance in association is shown in a tubular structure [58]. 
 
                              
Figure 1.9: A model of localisation and collaboration of A/B polarity complexes [59]. Crumbs/Stardust 
complex identifies the apical domain; Bazooka(Par3)/Par6/aPKC localise at the sub-apical region and 
Scribble/Dlg/Lgl complex lies at the baso-lateral domain. 
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The Crumbs/Stardust/PATJ complex establishes the apical identity of polarised cells and is 
required for the formation of the adherens junctions (AJs) in Drosophila and in 
mammalian epithelial cells. It consists of three main components: a transmembrane 
protein, Crumbs (Crb), and two adaptor proteins, Stardust (Sdt) and PATJ [54]   
The Bazooka(Par3)/Par6/aPKC complex is immediately below the Crumbs/Stardust/PATJ 
complex at the sub-apical region. It is composed of two scaffold proteins, Bazooka (Baz) 
or Par3, Par6 and an atypical Protein Kinase, aPKC. This complex defines the region in 
which the zonula adherens (ZA) is formed. In mammalian cells this complex localises at 
tight junctions and is required for AJs formation [54].  
The Scrib/Dlg/Lgl complex is linked to cell polarity and cell proliferation [60] and LOF 
phenotypes of these three TSGs are very similar [50].  
 
Scribble is a LAP (Leucine-rich repeats And PDZ domain) family protein and has four 
PDZ domains at the C-terminus and sixteen Leucine Rich Repeats (LRR) at the N-
terminus; it is encoded by a single gene both in Drosophila and vertebrates.  
Discs large is a MAGUK protein and contains three PDZ an SH3 and a GUK domain. 
Several mammalian orthologues of Drosophila dlg have been identified.  
Lethal giant larvae encodes a protein, Lgl, rich in WD40 repeats, predicted to fold into two 
β-propeller domains at the N-terminus, as its mammalian orthologues, Lgl-1 and Lgl-2 
[54]. Fly Lgl and human Lgl-1 show the significant sequence similarity of 62.5% (with 
conservative amino acids changes) associated with functional conservation: Lgl-1 
expression is indeed able, to substitute for Drosophila Lgl [61]. Analogue rescuing ability 
has been demonstrated for rat Dlg [62] and human Scrib [63]. These three proteins are 
mutually dependent for correct localisation [60] in Drosophila, although direct interactions 
have never been proven.  
Dlg and Scrib localise at the membrane cortex, at Drosophila septate junctions (SJs). Lgl 
co-localises with Dlg and Scrib at SJs but it is also found in the cytoplasm. It has been 
demonstrated that Lgl localisation at the membrane depends on its phosphorylation in 
conserved residues by aPKC of the Baz complex. When Lgl is phosphorylated its 
interaction domain is hidden, resulting in its exclusion from the cell cortex thus binding 
aPKC with Par6 excluding Bazooka (Par3) [64]. In fact, cortical spreading of aPKC in 
epithelial tissues causes Lgl inhibition at the baso-lateral domain with polarity defects, 
similar to what is observed in lgl mutants [65].  
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The Crb complex is recruited by the Baz complex at the apical domain and seems to 
further antagonise the activity of the Lgl complex by blocking its spreading along the 
lateral membrane domain. Crb is phosphorylated by aPKC and this event is required for its 
correct apical localisation. As expected from the high level of functional conservation, 
mammalian Lgl-1 and Lgl-2 are also excluded from the apical domain due to aPKC 
phosphorylation and are able to bind Par6 and aPKC preventing their association with Par3 
and thus the baso-lateral spreading of apical complexes [54]. Moreover Lgl-1 subcellular 
localisation seems to play a crucial role in human cancer, as its cytoplasmic enrichment 
correlates to aPKC lateral spreading and cancer progression in ovarian carcinomas [65]. 
 
1.4.3. lethal giant larvae and Tumourigenesis 
lgl LOF causes neoplastic over-proliferation in Drosophila imaginal epithelia and 
neuroblasts of the larval brain. These structures show loss of A/B polarity, sustained 
growth and disruption of tissue architecture which result in an over-extended larval period 
and pre-pupal lethality. Cell growth appears to be slow in lgl mutants; as lgl-/- cells are 
unable to exit cell cycle, discs reach an enormous cell number and eventually form large 
masses which fail to form proper cellular contacts and do not differentiate. 
 
 
                                
 
Figure 1.10: Wild-type (left) and l(2)gl4 (right) imaginal discs with evident over-growth and loss of layer 
organisation in lgl mutant epithelium [66]. 
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lgl mutants also show loss of positional cues, in fact cells straddle the anterior-posterior 
compartment  boundary [67], which separates two independent developmental units that 
never intermix. Moreover they are able to fuse with nearby tissues so displaying local 
invasiveness [68].  
Overgrowth might be hypothesised to be a direct consequence of loss of cell polarity in lgl 
mutant tissues. Loss of membrane compartmentalisation could indeed alter distribution of 
diffusible signals that regulate proliferation and their receptors, and delocalisation of 
signalling molecules both on cell surface and within the cytoplasm could result in 
simultaneous deregulation of several different pathways so triggering changes in cell 
metabolism and proliferation rate. Evidence exists that demonstrate a specific signalling 
function of the Dlg/Lgl/Scrib complex during proliferative control. In fact, polarity 
alteration by other means does not induce over-proliferation in imaginal discs, mutation of 
E-cadherin is the best example [69].  
It was demonstrated that the proliferative defects described above are due to the 
deregulation of the Hippo (Hpo) pathway, a very conserved signalling network that plays a 
central role in the control of epithelial organs, establishing for the first time a direct link 
between lgl and cell proliferation control [70].  
 
 
                
 
Figure 1.11: Hippo pathway components in  A) Drosophila melanogaster and  B) mammals [71].  
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The Hpo downstream effects are mediated by its effector: Yorkie (Yki) in Drosophila and 
YAP (Yes-Associated Protein) in mammals, a transcription factor regulated by two core 
proteins, Hpo and Warts (Wts), in Drosophila. Following physiological regulation, a large 
fraction of Yki is phosphorylated by Wts at multiple residues and sequestered in the 
cytoplasm by 14.3.3 proteins, but when a cell undergoes genetic or mechanical stress, core 
components are inactivated, unphosphorylated Yki enters nucleus and co-activates 
transcription of several target genes involved in cell growth and resistance to apoptosis, 
such cyc E (found over-expressed in lgl-/- clones [72], dIAP1 (Drosophila Inhibitor of 
APoptosis 1) and the miRNA bantam [73]. 
Mutations in major components of the Hpo pathway, including expanded (ex), fat (ft), 
Salvador (Sav) or wts, lead to competitive interactions that trigger death of the wild-type 
surrounding cells, revealing a competitive behaviour. This is caused by the hyper-
activation of Yki/YAP which is maintained in its unphosphorylated, nuclear form, 
increasing the expression of several targets involved in cell survival and proliferation [74]. 
A link between organ growth and nutrient availability has recently been found in the 
Drosophila wing with TOR (Target Of Rapamycine) regulating Yki downstream of the 
Insulin receptor by a separate and novel mechanism. TOR signalling controls nuclear Yki 
by allowing it to access to its target genes: when TOR activity is inhibited (low nutrients), 
Yki accumulates in the nucleus but is sequestered from its normal growth-promoting target 
genes, a phenomenon called "nuclear seclusion", thus scaling wing size downwards [75]. 
These were exciting findings because the Hpo pathway has only recently emerged as a 
major and highly conserved growth regulatory pathway that has also critical tumour 
suppressor functions [86] [89]. 
lgl was shown to take part in the regulation of this pathway: lgl mutant cells in the eye 
imaginal disc show upregulation of Hpo pathway target genes as cyclin E and dIAP1, as 
well as genes belonging to the negative feedback loops such as ex; consistently, in lgl-/- 
cells Yki was found to accumulate in the nucleus and the phosphorylated form levels were 
reduced. Removal of one copy of Yki partially reduced Hpo target genes, indicating that 
Yki activity is required for lgl-/- proliferative defects. lgl-dependent regulation of Yki has 
also been observed in the wing imaginal disc but it was proposed to occur through a 




	  	   27	  
1.4.4. Mammalian Lgl-1 and Lgl-2 
Mislocalisation, loss or decreased expression of Lgl-1/2 (in man, Hugl-1/2), suggest a role 
for these genes in tumourigenesis. It has been observed that Hugl-1 transcript results 
decreased or completely absent in variety of human epithelial tumours such as breast, lung, 
prostate, ovarian cancers, melanomas [61] [79] and colorectal cancer, where Hugl-1 loss 
was found to be associated with advanced stages and lymph node metastases [80]. Its loss 
has further been correlated with reduced survival in glioblastoma [81] and aberrant splicing 
variants with hepatocellular carcinoma progression [82]. Moreover, Hugl-1 seems to play a 
crucial role in ovarian carcinomas as its cytoplasmic localisation correlates to aPKC lateral 
spreading and cancer progression [65]. This clearly drives a strong parallel with the 
phenotypes observed in Drosophila lgl mutant epithelial tissues. Interestingly, pronounced 
similarities with the Drosophila lgl mutant were also found in Lgl-1 knock-out (KO) mice. 
Lgl-1-/- individuals presented at birth severe brain dysplasia due to an abnormal expansion 
of progenitor cells, unable to exit cell cycle and to differentiate. These cells formed 
neuroepithelial rosette-like structures, similar to the meroblastic rosettes found in human 
primitive neuroectodermal tumours (PNETs) occurring at pediatric age [83]. 
Noticeably, human Hugl-1 gene maps to 17p11.2, a region often shown to undergo 
chromosomal breakage in human PNETs [84]. Hugl-2 has been found to be a negative 
target of ZEB1, a master regulator of EMT [85] suggesting that its loss in epithelial cells 
may favour the acquisition of mesenchymal, migration-prone behaviour. 
 
1.5.  CELL COMPETITION 
 
“When the suspects give contrasting information, ask the neighbours:  
some of them will tell you exactly what is happening next door. Get ready to listen”. 
 
Cell competition (CC) is a non cell-autonomous phenomenon occurring between adjacent 
cell populations showing different fitness/proliferation rates. It was described for the first 
time in Drosophila melanogaster by Morata and Ripoll [86] while they were analysing the 
effects on organ development of a group of dominant, recessive-lethal mutations Minute 
(M) affecting various ribosomal proteins (Rp). The researchers demonstrated in the 
developing wing imaginal disc (the Drosophila larval primordium of the adult wing and 
thorax, see Section Materials and Methods) that the emergence of wild-type cells in a 
Minute background triggered a battle for field occupancy between the two cell populations: 
the wild-type population overgrew (Winner cells) and the Minute/+ cells, characterised by 
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a lower proliferative rate, lost the competition undergoing Caspase-3 mediated apoptosis 
(Loser cells) and disappeared from the adult organ. Contrarywise, Minute/+ clones 
generated in a homotypic context (in M/+ individuals) are viable and fertile, although they 
show an impairment in proliferation due to a low efficiency in ribosome assembly [86]. 
CC thus appears to be a mechanism of “quality check” that maximises tissue robustness 
through destruction of sub-optimal cells during development. 
 
Figure 1.12: Cell competition: pink cells are characterised by a higher proliferation rate than white cells. 




Mutations in Rp genes also occur in mammals. In 2004, it was observed that cells mutant 
for the mouse RpL24 riboprotein gene (Bst) were out-competed by wild-type cells in 
developing chimeric blastocysts [88]. This was the first time that CC was demonstrated to 
be at work also in mammals.   
Several molecules have emerged to be associated with the winner status by improving cell 
proliferation rate and cellular fitness, first in Drosophila then in mammals: one of them is 
the Decapentaplegic (Dpp)/TGFβ protein. 
Researchers found a reduction in Dpp signalling in out-competed cells. This molecule is 
involved in cell survival and when its pathway is active, it inhibits the transcription 
repressor Brinker (Brk), which would otherwise lead to the activation of the JNK pathway, 
causing death of the cells under competitive stress, that are eventually eliminated from the 
epithelium [89].  
Apoptosis is required for CC to occur; inhibition of cell death by the baculovirus IAP p35 
decreases winners’ proliferation rate and losers’ apoptosis. In fact, CC seems also to 
require the elimination of apoptotic cells by means of engulfment (phagocytosis) by 
surrounding tissue, as loss of function of genes involved in this process prevents 
competition [90]; a basal extrusion of the dead cells has also been frequently observed as a 
process to eliminate apoptotic cells [91].   
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Figure 1.13: Genetic impairments in the loser cells [92]: in “classical” CC, mutant cells (green) survive  in a 
homotypic environment (top), whereas they are eliminated when surrounded by wild-type cells (white, 
bottom). Subsequently, wild-type cells replenish the tissue by compensatory proliferation. Purple colour 
defines a winner fate. 
 
 
1.5.1. Phases of Cell Competition 
Based on the study of CC in the Drosophila imaginal wing disc, it has been possible to 
schematise the main phases of the mechanism. 
• Mutational events in cells that generate a reduced fitness creating a difference in 
proliferation or growth rate [93], metabolic rate or protein synthesis [94]. 
• Deprivation of morphogens and survival signals in loser cells, as it has been 
suggested by the “ligand capture” hypothesis by which cells compete for 
extracellular survival and growth factors [93]. 
• Both winner and loser cells “communicate” each other and actively participate in 
the competitive process, as Senoo-Matsuda and colleagues demonstrated that 
soluble factors from both populations are necessary for death of the loser cells [95]. 
Both populations are modified during the early stage of the process. SPARC [94] 
and FWElose  [96]  are up regulated in loser cells and the winner cells are 
characterised by a metabolic change, known as Warburg effect [97]. 
• Activation of apoptosis in the loser cells and, after that apoptotic bodies are 
extruded from the epithelium, phagocytic mechanisms start to clear the apoptotic 
debris [98].  
• Apoptosis-induced proliferation of the winner cells. CC is a process that assures an 
organ to reach a proper size with fit and functional cells composing it; unfit cells 
are promptly removed from the growing tissues and substituted by fitter cells, 
avoiding their expansion during development. Upon death and removal of unfit 
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cells, winner cells are stimulated to repopulate the developing organ undergoing 
additional proliferation, that has been named “apoptosis-dependent proliferation” 
because it does not occur if apoptosis is blocked in loser cells [56] [58]. 	  
 
1.5.2.  Mechanics of Cell Competition  
One hallmark of CC is the elimination of loser cells when they are close to winner cells, 
and this occurs through Caspase-3 mediated apoptosis [91] induced by signals emanated 
from both cell populations [95]. 
Caspase-3 induced apoptosis is a fundamental step for the progression of competitive 
interaction, and its inhibition has demonstrated to block CC [99]. 
Most of this apoptosis is observed at the boundary between two clones, winner cells and 
loser cells, as CC is based on direct cell-cell interaction between two different types of 
clones [100].  
Successively, winners cells can overgrow through apoptosis-induced proliferation [101] at 
the expense of the losers, as the final tissue/organ size is not reduced despite the 
elimination of loser cells [50] [51]. This suggests that dying cells secrete mitogenic factors 
which increase the proliferation rate of the neighbouring cells (via Dpp and Wg secretion, 
and the JNK-dependent secretion of Unpaired (Upd), the ligand of the JAK-STAT cascade 
in Drosophila) [92]. On the contrary, loser cells are less sensitive to these mitogenic 
signals.  
CC may require the function of the brinker (brk) gene, whose expression is normally 
repressed by Dpp signalling and is thus upregulated in slow-growing cells. Excess of Brk 
activates the JNK pathway, which in turn triggers apoptosis in these cells. The slow-
proliferating cells upregulate Brk levels owing to a disadvantage in competing for, or in 
transducing, the Dpp survival signal. This evokes the ligand-capture hypothesis and may 
function either in a short- or in a long-range fashion. This sequence of events might 
represent a general mechanism by which weaker cells are eliminated from a growing 
population [91].  
 
Recent work indicates that, in some cases, winner cells may not produce a specific pro-
apoptotic ligand. Instead it has been suggested that winner cells could be engulfing loser 
cells [102]. 
Mechanical stress has also been proposed to contribute to CC [103] [104] [105]. Qiang Sun 
and colleagues demonstrated as human cells can directly compete by a mechanism of 
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engulfment called entosis. Through entosis, cells are engulfed or cannibalised while alive, 
and subsequently undergo cell death. The researchers found that the identity of engulfing 
and engulfed cells is driven by mechanical deformity controlled by RhoA and actomyosin, 
where tumour cells with high deformability preferentially engulf and outcompete 
neighbouring cells characterised by low deformability in a heterogeneous population, 
demonstrating that a mechanical differential between winner and loser cells is required for 
entosis to proceed [56] [103]. 
Entosis, in association with emperipolesis, cannibalism and phagocytosis, describes the 
“Cell-in-Cell” mechanisms by which cells are internalised to undergo different fates. Part 
of these structures are associated with cancer, and function as tumour accelerators or 
tumour suppressors (fig 1.15). 
 
         
Figure 1.14: A dual role for entosis in cancer [106]. A) entosis as a pro-tumourigenic process. B) entosis as a 
tumour-suppressive mechanism.  
 
Another process indirectly associated with apoptosis in the epithelia is the eviction of cells 
from the epithelial sheet. This can occur either towards the apical surface (a process known 
as extrusion) or towards the basal surface (a process known as delamination). 
Delamination only disrupts cell-cell contacts, whereas extrusion causes detachment from 
the extracellular matrix, as well as loss of cell-cell contacts. In both cases, unless it is part 
of a programmed process such as EMT, exit from the epithelium leads to the loss of 
essential survival signals and thus apoptosis and phagocytosis [102].  
A recent study performed in MDCK cells provided evidence that crowding induces 
delamination. In fact, cell crowding may cause random buckling of weaker cells. In this 
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case, buckling would entail loss of the ability to withstand compression within the 
junctional area. Junctional buckling is expected to cause compensatory expansion of the 
cell surface elsewhere and hence activation of Piezo (a mechanically activated channel) 
[107]. Alternatively, cell compression could lead to other types of membrane deformation 
that could activate Piezo. This view suggests that compression and stochastic variations in 
the mechanical resilience of a cell are key to extrusion. As most compression probably 
occurs in fast-growing cells this view is unlikely to apply directly to CC, although a 
rigorous assessment will require three-dimensional modelling [102].                        
More recently, several studies identified MYC as a key regulator of CC. Clones of cells 
bearing hypomorphic dm mutations (the locus that in Drosophila encodes for the MYC 
protein, also known as dMyc), although viable in a homotypic environment, died when 
generated in a wild-type imaginal disc [108]. In 2004, two papers clearly demonstrated that 
this phenomenon was triggered by the difference in MYC expression levels between the 
two adjacent cell populations [93] [109]. 
 
1.5.3.  MYC/dMyc Oncoprotein 
MYC family proteins are evolutionarily conserved basic helix-loop-helix leucine zipper 
(bHLH-Zip) transcription factors that control about the 30% of all the expressed genes. 
They are involved in several cellular functions as: cell cycle progression, growth, 
metabolism, apoptosis, transcriptional and post-transcriptional regulatory mechanisms, 
non-coding RNAs, stem cell biology and cancer development. 
MYC oncoproteins can bind DNA at regulating regions, called E-Box sequences, 
following heterodimerisation with specific binding partners. Mammals possess three 
members of the MYC family: c-MYC, N-MYC and L-MYC (Figure 1.10).  
The c-MYC gene is ubiquitously expressed in dividing cells and normally downregulated in 
quiescent cells; N-MYC and L-MYC are expressed during particular stages of the 
embryonic development and in some immature hematopoietic and neuronal cells [65] [66]. 
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Figure 1.15:  The MYC family members [112]. The image at the top shows a generic representation of a 
mammalian MYC protein, indicating the transcriptional activation domain, the central portion, the canonical 
nuclear localisation sequence (N) and the region involved in DNA binding via interaction with MAX. Below 
is a representation of conserved sequences present in C-, N-, and L-MYC family members. c-MYC is drawn 
to scale at 439 amino acids. N- and L-MYC proteins are different in length (464 and 364 amino acids, resp.) 
due to differences in the length of non-conserved sequences, but are drawn to highlight the conservation and 
relative location of MYC boxes. 
 
MYC family proteins attained plain interest when their role in cancer development and 
progression was unveiled. Three mechanisms by which MYC oncoprotein can be activated 
and involved in cancer have been identified: insertional mutagenesis, chromosomal 
translocation and gene amplification. 
 
Early evidence for insertional mutagenesis involved in MYC-associated cancerisation 
emerged in the study of leukaemogenesis induced by avian myelocytomatosis retrovirus 
(MC29), an acutely transforming virus. Even if the scientific community was reluctant to 
accept the idea of a viral integration in human genome, the analysis of DNA and RNA 
from avian leukosis virus (ALV) and the analysis of RNA chimeras showed the existence 
of a viral-cellular integration in specific sites in the genome, often nearby an oncogene 
control region. MYC was the first cellular oncogene shown to be activated by retroviral 
promoter insertion [66] [68]. 
A genetic analysis of the Burkitt Lymphoma, a cancer of the lymphatic system 
characterised by MYC over-expression, revealed that the production of MYC mRNA 
resulted from a recombination between the immunoglobulin (Ig) heavy chain locus and the 
MYC oncogene [114]. This recombination came from a gross translocation of 
chromosomes 14, 2 or 22, which harbour the Ig heavy and light chain genes, to 
chromosomes 8, nearby the MYC gene coding region. The result of this translocation was 
the MYC mRNA transcription under the control of the strong Ig promoter. This evidence 
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was consistent with the finding, during the same year, of the Philadelphia chromosome 
involved in chronic myeloid leukaemia, that through the 22-9 chromosomal translocation, 
generated a fusion protein BCR-ABL responsible for the disease [115].  
 
Many different kinds of tumours are characterised by karyotypical abnormalities and the 
manner by which these aberrations can drive cancerous growth is also dependent on 
oncogene amplification. The role of MYC amplification involved in tumour emerged in the 
study of neuroblastoma. Amplification of N-MYC, normally expressed during neural 
development, was discovered in a panel of human neuroblastoma cell lines and tumour 
samples and was associated with poor prognosis [116]. 
In contrast to chromosomal translocations in haematopoietic cancers, activation of the 
MYC genes by amplification is commonly detected in human solid tumours [111].  
In the early 1980s, the debate about MYC was very rich of new daily findings and it 
became important to define the basic knowledge about the protein role in normal 
development. It was shown that MYC is a nuclear protein that binds double stranded DNA 
[117], whose stability and activity depend on Thr58 and Ser62 phosphorylations [118], and 
whose expression pattern is invariant throughout the cell cycle [119]. 
A direct link between mitogenic stimulation of quiescent cultured cells and a rapid 
induction of MYC mRNA was established in 1983: the highest RNA levels were reached 
within 2 hours from the mitogenic stimulus in the presence of cycloheximide, an inhibitor 
of protein synthesis. MYC mRNA and protein [67] [68] showed a short half-life and were 
both expressed at constant levels once cells entered cell cycle [119]. Anti-proliferative 
signals were shown to trigger a rapid decrease of MYC levels. These data indicated that 
MYC expression and activity are both tightly regulated in non-transformed cells and 
respond quickly to stimuli from the extracellular milieu.  
A multitude of signal transduction pathways have evolved to keep MYC expression under 
tight control. 
Drosophila MYC (dMyc), transcribed from the diminutive locus, is an onco-protein that 
shares both structure and function with its human homologue [58] [75]. 
dMyc contains several functional domains including the conserved basic helix-loop-helix 
zipper domain (bHLH/LZ) present at the C-terminus and used for dimerisation with 
Drosophila Max protein, the most conserved member of the Drosophila MYC network.  
At its N-terminus dMyc contains several conserved motifs including the conserved MYC 
Boxes I and II which are partially required for MYC transcriptional activities; the 
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conserved MYC Box III and IV containing the acidic region, whose mutation analysis 
revealed a novel conserved function in controlling MYC protein stability [120].  
 
                     
Figure 1.16: MYC proteins. Schematic representation of MYC proteins [121]. Comparison between human 
c-MYC and Drosophila d-MYC oncoproteins.  
 
 
Experiments where Drosophila Myc cDNA was used to rescue proliferation defects of 
mouse embryonic fibroblasts from c-MYC mutant mice [122] and developmental defects 
of Drosophila dmPG45 hypomorphic mutants were rescued by expression of human c-MYC 
cDNA [123] demonstrated that Drosophila and vertebrate MYC can functionally substitute 
each other. Moreover these results showed that many MYC functions are conserved from 
insects to mammals. 
MYC protein family exerts several activities, most of them through the MYC/MAX/MNT 
complex. MYC is largely responsible for growth control and organ size: overexpression of 
dMyc in large territories of the Drosophila imaginal disc induces growth by accelerating 
the G1/S transition of the cell cycle, while entry into the M-phase is limited by the 
availability of other molecules developmentally expressed (e.g. CDC25), thus limiting 
hyperproliferation [121]. 
MYC influences the expression of a large set of genes involved in several cellular 
processes and a preeminent group of MYC-activated targets encode for proteins involved 
in ribosome biogenesis and energetic metabolism [124]: MYC involvement is also 
demonstrated in the regulation of metabolic pathways such as glycolysis and 
glutaminolysis [125]. 
Moreover, high levels of Myc in Drosophila are demonstrated to cause cell-autonomous 
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1.5.4. MYC-Mediated Cell Competition (MMCC) 
CC collected the interest of cancer researchers when it was associated to cancer through 
the discovery of super-competitors. Super-competitor mutations increase cell fitness and 
lead to clonal overgrowth at the expense of the surrounding wild-type tissue, similarly to 
what happens in the early stages of tumour progression [127]. 
             
Figure 1.17: ”Super-competitors” [92]: supercompetitor cells (light purple) do not induce apoptosis when 
surrounded by cells with the same genotype (top), whereas they can grow at the expenses of the surrounding 
wild-type cells (white) by inducing their death (bottom). Growth of the winner cells is induced by 
compensatory proliferation through the secretion of Dpp, Wg, Hh, and Unpaired from the dying cells (dark 
gray arrow), or a non-cell autonomous down-regulation of the Hippo pathway induced by dying cells (not 
depicted). Purple cells are the winner cells, green cells are the loser cells. 
 
Clones expressing high dMyc levels within a wild-type tissue overgrow at the expense of 
the surrounding tissue to fill all the compartment [86] [101]. Clone expansion requires the 
elimination of the surrounding loser cells through Caspase3-mediated apoptosis; these 
wild-type loser cells appear to be eliminated within eight cell diameters away from the 
MYC-expressing cells [109] as CC seems to be mediated by soluble factors [95]. 
Similar evidence was found using a tandem duplication model, in which sibling clones 
resulted composed of cells expressing four copies (4xdmyc) and two copies (2xdmyc) of 
the diminutive (dm) gene. In these experiments the 4xdmyc clones were larger than the 
2xdmyc clones and also larger than 4xdmyc clones growing in a homotypic background; 
similarly, the 2xdmyc clones were smaller then nearby 4xdmyc clones and also smaller 
than 2xdmyc clones growth in a homotypic background. The meaning of these studies is 
that the cellular behaviour is not fixed by genotypes but is adaptable to different contexts, 
and that the competition is based on relative and not absolute levels of MYC [93]. 
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Figure 1.18: Cell Competition in tissues mosaic for cells with different copy numbers of the dmyc gene [93]: 
A) control twin clones which both express two copies of dmyc. B) experimental clones which either express 
four (GFP2+) or two copies (GFP-) of dmyc. The 4xdmyc clones are larger than the 2xdmyc clones. C) control 
twin clones which both express four copies of dmyc. 
 
As MYC has a role in ribosome regulation, it has been hypothesised that MMCC may 
require its ability to influence ribosomal activity. Consistent with this idea, MYC-
expressing clones bearing a ribosomal protein mutation were no longer able to out-compete 
surrounding cells [93]. Directly, the under-regulation of protein synthesis seems not to be 
sufficient to trigger MMCC, since the expression of PI3K (protein synthesis regulator) was 
demonstrated to be unable to induce CC [109]. 
The phenomenon of CC is mediated by different accessibility to growth signals: winner 
cells, due to their optimal growth status, would be able to capture more survival factors 
than loser cells, that instead would die by JNK-mediated apoptosis. To confirm this 
hypothesis and to test the “rescue” properties of some genes implicated in cell growth, 
researchers carried out a CC assay inducing mutant clones of the chosen genes in a MYC-
overexpressing background: mutations that provided cells with an advantage in this 
competitive context were defined “super-competitors”. 
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Figure 1.19: MYC-mediated CC [128]:  A) a clone of cells with genotype A is viable in a homotypic 




1.5.5. Factors Involved in Cell Competition 
CC is a process that requires communication between distinct cell populations. However, 
the molecular mechanisms underlying this dialogue are still unclear [102]. 
MMCC seems to be also mediated by soluble factors [95]. The study was carried out on 
Drosophila S2 cells, where cells over-expressing MYC and control, GFP-positive cells, 
were co-cultured. The two populations were separated by porous filters that were 
permissive only to the transit of soluble molecules. Over a short period of time, the control 
GFP-positive cells were induced to die, while death of the MYC-expressing cells did not 
increase above background, demonstrating that CC did not require a cell-cell contact. In 
addition, medium from co-culture experiments was able to induce death of wild-type cells 
and not MYC-expressing cells when plated in single plates, and medium from single 
cultures was not sufficient to trigger CC, demonstrating that both populations are needed to 
trigger competitive behaviours.  
Another important evidence about factors released into the competitive medium has been 
collected in a recent work. Patel and colleagues carried out a miRNAs multiple screening 
by which they identified miRNAs that target conserved CC-related genes in Drosophila 
melanogaster. This study led to the identification of nine potential CC-associated miRNAs 
in the Drosophila genome and, importantly, eighteen human homologs of these nine 
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potential Drosophila miRNAs are well reported for their involvement in different types of 
cancers [129].    
CC can also be mediated by membrane proteins as Flower (Fwe), an evolutionary 
conserved membrane channel protein. Different Fwe isoforms were observed to tag 
“winner” and “loser” cells in Drosophila imaginal epithelia. Fwe is present in three 
isoforms with different C-terminal extracellular domains; the Ubi form is constitutively 
expressed by the epithelial cells of the discs, while the Lose-A and Lose-B forms are only 
present in the loser cells. The confrontation between the Ubi and the Lose forms was 
postulated to be the cause for loser cells to die, since knockdown of the fwe gene resulted 
in a reduced expansion of clones over-expressing MYC [96]. 
Another factor known to mark loser cells in Drosophila is SPARC (Secreted Protein 
Acidic and Rich in Cysteine). This molecule has a protective role in loser cells because its 
expression inhibits Caspase-3 activation. Like Fwe, SPARC seems to be actively expressed 
during CC as there is no rescue of apoptosis out of a competitive context [96].  
 
1.5.6. The Hippo Pathway and Cell Competition 
In both Drosophila and mammals, the Hpo signalling pathway regulates growth by 
preventing the transcriptional co-activator Yki/YAP (Yes Associated Protein) from 
entering nucleus and activating its downstream targets [77] . 
Epithelial cells show strong polarisation along the apical-basal axis and epithelial cancer 
cells often exhibit absence or mislocalisation of polarity proteins and MYC upregulation 
[121].   
Oncoprotein MYC is a transcriptional target of Yki/YAP and through a mechanism of 
negative feedback regulates MYC at both the transcriptional and post-transcriptional levels 
[130]. When MYC is downregulated in Yki-overexpressing clones these is no death of the 
surrounding cells, suggesting that MYC is the driving force of Yki-induced competition, 
and that relaxation of the Hpo pathway does not induce CC on its own, but it rather acts 
through direct regulation of MYC expression [77]. 
Drosophila lgl and its human homologue HUGL-1 [61] are TSGs encoding scaffold 
proteins involved in the maintenance of A/B polarity in the epithelial cells. The mutant 
phenotype of these genes is dictated by the context in which the clones grow. In a 
homotypic context, cells mutant for lgl overgrow leading to the formation of a neoplastic 
mass (figure 1.19 A adapted: suboptimal cells are lgl-/- mutant clones ) [131]; conversely, if 
the clones are surrounded by wild-type cells, they are eliminated from the tissue by the 
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activation of the JNK pathway (figure 1.19 B adapted). Overexpression of MYC in the   
lgl-/- clones not only rescues their viability but promotes malignant growth and induces 
death in the surrounding wild-type cells, turning lgl-/- cells from losers into super-
competitors (figure 1.19 C adapted) [132].  
Cells depleted of lgl show nuclear accumulation of the transcription factor Yki, where it 
can promote the expression of genes involved in cell survival and proliferation, among 
which MYC plays a role in transforming these cells into super-competitors [93]. 
Deregulation of the Hpo pathway also contributes to the overgrowth that characterises the 
oncogenic cooperation between activated Ras/Raf and polarity gene loss [133]. Yki targets 
are indeed upregulated in RasV12; lgl-/- tumours.   
The constitutive activation of the oncoprotein Ras (e.g. RasV12) in cells mutant for lgl leads 
to the formation of growing neoplastic masses capable to invade and to create metastasis. 
The effect of RasV12 on the neoplastic mutant cells appears to include super-competitive 
properties provided by a cell-autonomous increase in MYC expression. Mutations in the 
Hpo pathway give rise to hyperplastic growth, thus a cooperation between loss of apical-
basal polarity and hyperplasia seems to be necessary and sufficient for pushing the cells 
towards a malignant phenotype. 
MYC has been identified as a downstream effector of the Hpo pathway also in mammals; 
YAP promotes c-MYC transcription in a hepatocellular carcinoma mice model [121] and 
both are necessary for carcinogenesis in a nude mouse model [134]. YAP shows nuclear 
accumulation in several human tumours, partly associated with high MYC expression 
[135]. 
 
1.5.7. MMCC in Mammals  
A decade later its discovery in Drosophila, MMCC was also found involved in mammalian 
development. Researchers induced functional genetic mosaics in the mouse and observed 
that imbalanced MYC levels in the epiblast (an early embryonic structure) were sufficient 
to induce the expansion of MYC over-expressing cells at the expenses of the wild-type 
cells, which were eliminated by apoptosis. Moreover, they noticed that wild-type cells 
composing the early embryo were heterogeneous in MYC content during development 
with a CC-like mechanism to refine the final epiblast selecting for cells with higher MYC 
levels [136]. 
Sancho and colleagues observed that defective embryonic stem cells underwent apoptosis 
during embryo development through a mechanism driven by MYC differences within the 
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embryo [137]. The first experimental evidence suggesting a role for MMCC in mammalian 
carcinogenesis was carried out in a familiar polyposis murine model, where APC cells 
deprived of c-Myc were out-competed by surrounding, c-Myc expressing wild-type cells, 
reverting the malignant phenotype [138]. An example of MMCC in mammals comes from 
a work conducted by Mamada and colleagues in 2015. The researchers established an in 
vitro model system that showed CC in mouse NIH3T3 embryo fibroblast cells. Co-culture 
of TEAD activity-manipulated cells with normal cells caused CC. Cells with reduced 
TEAD activity became losers, while cells with increased Tead activity became super-
competitors. TEAD is a target that YAP binds to control cellular response and directly 
regulated Myc RNA expression, and cells with increased Myc expression became super-
competitors [93] also in mouse [136]. The researchers demonstrated that NIH3T3 cells 
show CC mechanisms similar to those regulated by Yki and Myc in Drosophila [139] . 
 
1.5.8. Cell Competition and Cancer 
The origin of the vast majority of human tumours is monoclonal, descending from single 
progenitor cells through several rounds of mutation and selection, finally establishing a 
detectable mass. Even if an advanced mass is simple to find and to study, it is difficult to 
track early events. These initial events are vital for tumour progression and their 
understanding might help  treat cancer successfully. CC may act during the early stages of 
cancer progression, where clones characterised by high fitness out-compete the unfit.   
The initial expansion may increase the probability of accumulation of other mutations in 
subsets of cells, that would confer new oncogenic properties. As tumours are very 
heterogeneous, CC might provide a further selection for some kind of rapidly growing 
cells. In fact, hundreds of mutations are present and selected during cancer development. 
Selection mechanisms reflect interaction between tumour and normal cells during the 
progression of cancer. Some of these mutations may be selected through effects of CC, so 
they might not be required for tumourigenesis but might affect the chances of progression. 
Tumour cells may out-compete normal cells, such as super-competitors out-compete wild-
type cells [140]. The first gene that demonstrated to induce CC in Drosophila when over-
expressed was dMyc. Clones of wild-type cells are out-competed when nearby cells 
express high dMyc levels [50] [75]. Contemporary, researchers found that mutations 
inactivating the Hpo pathway can also cause super-competition in the presence of wild-type 
cells [141]. As Myc family genes and deregulation of Hpo pathway components are 
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involved in cancer, super-competitors have been hypothesised to be involved in the early 
stages of cancer progression.  
Very recent evidence produced by two research groups defined the involvement of CC in 
different stages of tumour progression. Suijkerbuijk and colleagues demonstrated the 
involvement of clonal competition in driving the growth of tumour mass in a Drosophila 
model of APC-/- intestinal adenomas. Adenomatous APC-/- cells showed higher Yki/YAP 
activity via JNK pathway activation than wild-type surrounding tissue. Moreover they 
demonstrated that the prevention of CC through apoptosis inhibition restored host tissue 
growth and contained adenoma expansion, focusing on the importance of CC in adenoma 
progression in flies [142]. Eichenlaub and colleagues provided evidence that, in a 
Drosophila epithelial cancer model, CC drives primary tumour formation and secondary 
tumour progression. Cells expressing EGFR together with the conserved microRNA miR-8 
acquired super-competitive properties. Activating mutations in EGFR have long been 
recognised as driver mutations in human cancer. EGFR overexpression in wing imaginal 
disc cells leads to tissue hyperplasia, with accelerated cell proliferation accompanied by 
increased apoptosis. When combined with cooperating factors as miR-8 expression, a 
microRNA shown to downregulate the expression of the Septin family protein Peanut, 
involved in cytokinesis failure, EGFR overexpression can lead to neoplasia and metastasis 
through the induction of apoptosis and engulfment of the nearby wild-type cells [143].  
In recent years, researchers postulated two different outcomes for CC during the early 
stages of tumour progression: “field cancerisation” [144] and elimination of pro-tumour 
cells, as an intrinsic tumour suppressor mechanism, to protect tissue from the very early 
mutated clones on the onset of tumour development [83] [102] [110]. 
The concept of field cancerisation was first introduced to explain the presence of 
histologically abnormal tissue surrounding oral squamous-cell carcinoma. According to 
one model, a cell sustains an initiating mutation. After massive proliferation, some of its 
clonal descendants may acquire a second mutant allele, and “initiated” cells may then 
proliferate and eventually occupy a large field of epithelium in which the chances of 
development of a malignant neoplasm are higher [100]. Field cancerisation has been 
observed in many epithelia, including  the head and the neck region, lung, bladder, cervix, 
colon, breast, Barrett oesophagus and actinic keratosis, dysplastic precursors of squamous 
cell carcinoma [128]. 
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1.6.  p53 PROTEIN FAMILY 
 
As p53 TSG has been found to be mutated in more than 50% of human cancers, it has 
attracted the interest of numerous researchers [146].  
p53 protein was first identified in 1979 as a transformation-related protein characterised by 
a strong accumulation in cancer cell nuclei, able to bind simian virus 40 (SV40) large T 
antigen [147] and showing oncogenic activity. About 10 years later it was shown that those 
forms of the p53 protein were the result of missense mutations [148] and evidence from the 
first KO animal models, during the early 1990s, clarified the central role in tumour 
suppression of wild-type p53 [149]. During the years, several biological functions have 
emerged in which the p53 protein plays fundamental roles, such as apoptosis, 
development, differentiation, DNA recombination and cellular senescence [150]. 
p53 is part of a protein family including two other members: p63 and p73 [151] [152], 
considered the ancestors of p53 for the strong structural and functional relations: p53 
seems to have evolved a tumour suppressive function in higher organisms [152]. The 
human gene encoding the p53 protein, TP53 (tumour protein 53), spans a 20 kb region on 
chromosome 17 [153]. Human p53 is a nuclear transcription factor of 53 KDa composed of 
393 amino acids organised in several structural and functional domains [154]. The central 
region of p53, p63 and p73 is evolutionary conserved in humans, Drosophila melanogaster 
and Caernorhabditis elegans [155] and structural studies have revealed that majority of 
p53 missense mutations found in cancers are located in this region [156]. 
 
          
Figure 1.20: A schematic representation of the p53 structure with the hot spot mutation region and the 
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1.6.1. The Physiological Functions of p53 
During the last 40 years, plenty of evidence demonstrated how p53 can be considered one 
of the main regulators of cell integrity. 
Many genes have been found to be transcriptional targets of the protein, as wild-type p53 
can be activated by a number of stresses within the cell, including hypoxia, DNA damage 
and oncogene activation [157].  
During cell life, wild-type p53 protein is present and sequestered by the Mouse Double 
Minute 2 homologue (MDM2), so its transcriptional activity is inhibited. MDM2 is an 
important negative regulator of the p53 tumour suppressor protein and functions both as an 
E3 Ubiquitin ligase that recognises the N-terminal trans-activation domain (TAD) of 
the p53 protein, and as an inhibitor of p53 transcriptional activation [158]. Additionally, a 
homologue of MDM2, MDMX, also serves as a negative regulator of p53, as MDM family 
members are found overexpressed in a myriad of neoplasms showing nonfunctional wild-
type p53 [159]. 
In response to various types of stress, p53 enters nucleus, carries out its functions as a 
sequence-specific transcription factor, acting as a homotetramer and binding to p53 
response elements on inhibiting cell cycle progression, promoting senescence, inducing 
apoptotic cell death or acting in metabolic processes [157] [160] [161]. Beside this, 
protein-protein interactions may be implicated in other functions of the protein [162]. 	  
The downstream targets are differentially activated depending on the cell type, on the 
damage and on various other not already identified parameters. 
p53 exerts its role on cell cycle progression and genome stability by inducing a transient 
G1 cell cycle arrest in response to DNA damages [146]. 
One of the most important functions of p53 is to induce apoptosis in damaged cells. p53 
transcriptionally activates the expression of several pro-apoptotic BCL-2 family proteins 
and, by interacting with pro-apoptotic and anti-apoptotic factors in the cytoplasm and at the 
mitochondrial membrane, it can lead to the activation of caspase-induced apoptosis. 
Additional experiments showed that disruption of the apoptotic pathway downstream of 
wild-type p53 by overexpressing BCL-2 or dominant-negative forms of the caspase 9 
promotes lymphomagenesis [163]. 
p53 may also induce senescence in response to oncogene activation or telomere 
dysfunction and is dependent on the p53-mediated transcriptional activation of p21, which 
is a cyclin-dependent kinase (CDK) inhibitor that halts the cell cycle in the G1 phase. 
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The maintenance of cellular homeostasis is a p53 role performed in case of metabolic 
stress when cells go through starvation. Upon glucose deprivation, MDH1 (Malate 
DeHydrogenase 1), the enzyme that catalyses the reversible oxidation of malate to 
oxaloacetate, recruits p53 and stabilises it inducing cell cycle arrest [164]. AMPK, a 
nutrient stress sensor, activates p53 by phosphorylation or acetylation [165]. This 
mechanism involves also ribosome proteins that sequester MDM2, favouring p53 over- 
expression [166]. 
 
In metabolism, p53 protein plays its role by limiting the glycolytic rate through the 
inhibition of glucose uptake by the glucose transporters type 1, 3 and 4 (GLUT1, 3, 4), 
This in turn slows glucose oxidation to pyruvate by phosphofructokinase 1 (PFK1) and 
phosphoglycerate mutase (PGM) through direct or indirect inhibition of these enzymes. 
This is followed by promotion of pyruvate conversion in acetyl-CoA and upregulation of 
the mitochondrial oxidative phosphorylation [167]. The balance of glucose metabolism in 
favour of energy production is physiological in some organs, as heart and brain. Until p53 
is active, it promotes cell survival maintaining metabolic homeostasis, and when the wild-
type p53 function is lost, cancer cells can however survive and divide by exploiting the 
glycolytic switch [168]. This metabolic switch that increases glycolytic flux, typical of 
cancer cells, is known as the Warburg effect [169]. 
Another important aspect of a tumour is the capacity to interact with the immune system: 
p53 participates also in this aspect by inducing the activation of cytokines and pro-
inflammatory agents that act to decrease tumour size and angiogenic potential [170].  
 
1.6.2. p53 as a Tumour Suppressor 
First evidence about p53’s role in cancer biology was found in late 1960s, when germline 
mutations in TP53 were associated with the Li-Fraumeni Syndrome (LFS), an autosomal 
dominant disorder predisposing individuals to breast cancer, sarcomas and other neoplasms 
[171] [172] [173]. 
p53 is not involved in physiological development, but animals harbouring a p53 deletion 
are extremely cancer-prone [149] [174]. Loss of p53 in human tumours induces formation 
of more aggressive and vascularised masses [175]. 
Nowadays it is widely acknowledged that p53 compromised functions are the most 
common genetic events in human cancer [150]: while almost 50% of all tumours exhibit 
mutation of p53, in many other its normal function is attenuated by several mechanisms 
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acting in its modulation as the up-regulation or activation of negative regulators, as MDM2 
or MDMX found over-expressed in a variety of neoplasms. [158].  
In addition to the discussed roles of p53 in cell cycle regulation, senescence and apoptosis, 
further functions are associated with the inhibition of differentiated cell reprogramming to 
pluripotent stem cells (PSCs), [176] so it is plausible that p53 suppresses tumourigenesis 




Figure 1.21: The Stress Response Pathway, in which p53 protein exerts several functions by activating 
different downstream targets [146]. 
 
1.6.3. p53 and the “Gain of Function” Hypothesis 
A difference between p53 and many other TSGs is the appearance of a huge number of 
missense mutations along its sequence: the vast majority of tumour suppressors, in fact, is 
inactivated by deletions [177], but in p53, a great number of cancer-associated mutations 
are single base substitutions resulting in a full-length active protein [178]. 
The mutational hot spots in the p53 sequence are concentrated in the region encoding the 
DNA-binding domain (Fig 1.16). The mutant products fall into two broad categories: the 
 Contact mutations, affecting residues involved directly in DNA contacts without altering 
p53 conformation, and the Structural mutations, that cause a conformational change in the 
core domain [179]. While wild-type p53 has a very short half-life when unreleased, some 
of these stable mutants have a prolonged half-life and can create precipitates inside cancer 
cells’ nuclei [180] [181] [182].  
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Many of these stable mutants of p53 can exert a dominant-negative (DN) effect on the 
remaining wild-type  protein [183] and such dominant activity may be affected by either 
formation of mutant/wild- type p53 co-tetramers or by the incorporation of the wild-type 
form into mutant tetrameric aggregates [184]. Interestingly, missense mutation of p53 are 
often followed by Loss of Heterozygosity (LOH) at the corresponding locus [185] [186].  
The sum of all these observations led researchers to elaborate the “gain of function” 
hypothesis, either because many missense mutations of p53 are not equivalent to its loss of 
function, or because the strong selection of some of these forms upon the wild-type p53 
protein suggests an important role in tumourigenesis.  
There is also evidence that mutant p53 exerts its pro-oncogenic activities independent of its 
effects on the wild-type form [187] and many studies have also demonstrated a poor 
prognosis for many kinds of human tumours with missense mutations of p53 [178]. p53 
pro-oncogenic activity may be carried out through tree different mechanisms: first, tumour 
cells could be selected for loss of wild-type p53; second, p53 mutants could lose their 
tumour-suppressive functions while retaining other aspects that can be involved in 
tumourigenesis: third, mutant p53 proteins could acquire neomorphic activities that 
improve cell performance and tumour growth [188].  
 
1.6.4. p53 and Cell Competition 
Myc supercompetitor behaviour in Drosophila melanogaster has been demonstrated to be 
dependent on the p53 wild-type function [168] by de la Cova and colleagues in 2014. 
Researchers have analysed an increase in metabolic requirement of Myc-overexpressing 
cells during CC. This increased requirement is not observed in cells of the same genotype 
growing in a homotypic context. 
Myc protein overexpression alters mitochondrial morphology and impairs COX activity of 
complex IV (a common trait in many cancers) which results in a reduced electron transport 
chain and in a reduced cellular ATP pool, followed by an increased glycolysis, a typical 
trait of cancer cells described as the Warburg effect [169]. The role of p53 is to balance 
these stressful metabolic changes occurring in Myc-overexpressing cells (where p53 
mRNA is increased) by promoting OXPHOS and restraining glycolysis [168]. COX 
deficiency and low steady-state ATP levels are accompanied by a p53-dependent increase 
in scox mRNA, the cytochrome c oxidase 1 homologue in Drosophila [189], to maintain 
metabolic homeostasis and assure fitness protection to Myc-overexpressing cells.  
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In competitive co-culture assays, p53 inhibition by p53 dsRNAs downregulates glycolysis 
in Myc-overexpressing cells, and glut1 and glut3 expression is abolished. The result of this 
metabolic change is that Myc super-competitor cells lose their capability to out-compete 
loser cells and to expand and colonise the tissue [168]. 
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The Aim of the Study	  
 
Tumour is a complex and heterogeneous disease in which cancer cells, in constant 
communication with their surrounding environment, undergo selective processes aimed at 
gaining strength and malignancy in order to protect their unlimited replicative power and 
ensure potentially endless descendants.  
 
The aim of this study is to find an essential signature of MYC-mediated cell competition in 
human cancers and demonstrate a role for this phenomenon in shaping cancer evolution 
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                                                                                             Chapter 2 
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2.1.  Definition of an Essential Signature of MYC-Mediated Cell Competition in 
Human Epithelial Cancers  
In Drosophila, dMyc oncoprotein was found to play a role in transforming cells into super-
competitors able to overgrow at the expense of surrounding non over-expressing dMyc 
cells that are eliminated by Caspase-3 mediated apoptosis [93].  
cMYC over-expression is frequently observed in human cancers [112]. 
cMYC transcription is promoted by YAP (Yes-Associated Protein) in several carcinoma 
mice models [121] and both these proteins are necessary to induce carcinogenesis in nude 
mouse models [134]. YAP is found accumulated in the nucleus of several human tumours 
and it is frequently associated with a high cMYC expression profile [135].  
YAP (Yki in Drosophila) nuclear translocation is induced by Hpo pathway alterations in 
both Drosophila and humans [190]. These alterations can be triggered by many physical 
and biochemical stimuli [191] among which loss of A/B cell polarity is prominent in 
epithelial carcinogenesis [50]. HUGL-1/Lgl delocalisation/absence [61] has been 
demonstrated to cause YAP/Yki nuclear translocation in human and Drosophila cancers. 
[65] [79] [80] [82]. 
To verify if signs of MMCC were present in human carcinomas, I hence defined an 
essential signature of CC in which cMYC overexpression was searched within tumour cells 
in association with HUGL-1 mislocalisation/absence and YAP nuclear enrichment, as both 
are involved in Hpo-dependent cMYC overexpression, and Caspase-3 positive cells were 
searched out of the tumour mass. 
 















cMYC/Cas-3 HUGL-1 YAP-1 





Figure 2.1: IHC on human carcinomas (I: colon, II: lung, III: breast lobular, IV: breast ductal) and respective 
secondary lesions (I a: liver , II a: brain, III a: lymph node, IV a: lymph node). Comparison of the same 
regions.   A. Double staining for cMYC (pink) and Cleaved Cas-3 (brown) B. Staining for HUGL-1 (brown) 
C. Staining for YAP (brown). Black arrows indicate tumour clones, red arrows indicate lower cMYC levels 
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In the great part of the samples investigated it was possible to see as MMCC is engaged 
between tumour cells and the surrounding stromal cell populations. 
As expected, tumour cells (red arrow) are characterised by HUGL-1 cytoplasmic 
localisation/absence, YAP nuclear persistence and cMYC upregulation, while surrounding 
stromal and immune cells, characterised by a lower cMYC expression level (black arrows), 
are positive to Cleaved Caspase-3, suggesting they are undergoing apoptosis. 
This evidence indicates that CC driven by local differences in cMYC expression is a 
mechanism by which either primary epithelial tumours and respective metastases (with 
characteristic loss of A/B polarity and deregulation of the Hpo pathway) with high cMYC 
levels lead, while expanding, the surrounding non-tumour cells to apoptotic death. 
Potentially, CC persists until a difference in cMYC levels is found between neighbouring 
cells. 
 
2.2. Clone Competition - MMCC Within the Cancer Mass. 
An interesting observation emerged while analysing the IHC slides in search of CC 
markers: MMCC seemed to exist even within different tumour cells. In Figure 2.2, 
adjacent tumour masses are characterised by different patterns of HUGL-1 and YAP (fig 
2.2 B and C, black arrows) and different cMYC levels (fig 2.2 A, black arrows). The mass 
showing lower cMYC levels displays some cells positive to Cleaved Caspase 3 antibody 
(fig 2.2 A, red arrow), revealing an elimination in progress. This evidence suggests a role 
for cMYC in clone selection. This kind of MMCC will be referred to as Clone competition. 
 
   
 
Figure 2.2: IHC on a colon carcinoma sample. Comparison of the same region in sequential slices.  A. 
Double staining for cMYC (pink) and Cleaved Cas-3 (brown) B. Staining for HUGL-1 (brown) C. Staining 
for YAP (brown). Black arrows indicate tumour clones, the red arrow indicates lower cMYC and Cleaved 
Cas-3 positive clones. 200X magnification. 
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Signs of clone competition were found in a large panel of primary carcinomas (fig. 2.3 A) 
and correspondent secondary tumours (fig 2.3 B), where tumour clones surrounded by 





Figure 2.3: IHC on several primary (A) and corresponding secondary (B) tumours, MYC (pink) and Cleaved 
Cas-3 (brown). I- A. Ductal breast carcinoma I- B. Lymph node metastasis II- A. Lung poorly differentiated 
carcinoma II- B Brain metastasis III-A. Colon adenocarcinoma III- B. Liver metastasis. Black arrows 
indicate cancer clones characterised by low MYC expression and Cleaved Cas-3 positive staining. 200X 
magnification. 
 
Taken together, these results obtained by IHC analysis let us hypothesise an important role 
played by MMCC during carcinogenesis: while CC is useful to shape the tumour mass, 
enhancing growth at the expense of the surrounding tissue, the mechanism of clone 
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elevated cMYC oncoprotein levels. Cell competition and clone competition can be seen as 
two faces of the same coin, playing integrative roles in promoting malignancy and 
aggressiveness of solid tumours. This study on CC seems also to suggest that elimination 
of the weaker cells allows the stronger population to overgrow [93] [130].  
 
2.3. An in Vitro Model to Study MMCC in Genetically Distant Cells 
IHC analysis revealed that signs of MMCC are present in primary and secondary tumours, 
and this phenomenon seems to occur both between cancer/stromal cells and cancer/cancer 
cells characterised by a different expression of cMYC oncoprotein. MMCC has been 
demonstrated to be at work in vitro in Drosophila cell lines [95] [168] and in mouse 
fibroblasts [139] but its role has never been investigated between different cancer cells.  
To evaluate whether cMYC protein differences are sufficient to drive CC between 
genetically distant cancer cells, I performed Cell Competition Assays (CCAs). CCA is an 
in vitro cell assay designed to assess competitive interactions occurring between co-plated 
cell populations compared to their behaviour in separate conditions.  
I performed CCAs using two cell line pairs coming from different carcinomas: lung 
carcinoma H460 and H1975, colorectal carcinoma LS174T and LoVo. All the cell lines 
were previously characterised  for cMYC levels (figure S.I. 1). 
The first assay has been performed between lung carcinoma cell lines: H460 and H1975 
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Figure 2.4: CCA on H460 and H1975 lung cancer cell lines. Co-cultured cell lines, indicated with cc, 
represent the first two bars of each graph; separated cell lines, indicated with sep, are the second two bars of 
each graph. A) Growth after 5h of culture; each assay was repeated 3 times and counted twice. B) Apoptotic 
cell percentage calculated by IF after 5h of culture. H1975 cell line shows the highest Caspase-3 percentage 
when co-cultured with H460. Each IF was repeated 4 times and 4 fields were counted in each slide. ± SEM is 
indicated.  
    
As can be seen in Figure 2.4 A, H460 cell line in co-culture (red bar) showed a 
significantly higher growth rate than the H1975 in co-culture (blue bar) and than H460 in a 
separate condition (red striped bar), showing high competitive advantage; H1975 showed a 
significant decrease in growth units in co-culture (blue bar) compared to its growth in a 
separate condition (blue striped bar).  
The level of Cleaved-Caspase 3 positive cells in the loser population was more than three 
times higher compared to the same cell population in separate conditions (Fig. 2.4 B, blue 
bar), defining a competitive interaction between the two cell lines in which winners 
induced the losers to undergo apoptosis. The increase of apoptosis in co-culture is a 
consequence of the activation of competitive interaction between the two populations and 
explains the low cell number found after the CCA. From the CCA and the Cleaved-
Caspase 3 IF we can infer that cells carrying higher cMYC levels are able to out-compete 
genetically different cells with lower MYC levels.  
The CCA was repeated using other two cell lines from different cancers (colorectal 




	  	   60	  
 
Figure 2.5: CCA on LS174T and LoVo colon cancer cell lines. Co-cultured cell lines, indicated with cc, 
represent the first two bars of each graph; separated cell lines, indicated with sep, are the second two bars of 
each graph. A) Growth after 5h of culture; each assay was repeated 4 times and counted twice. B) Apoptotic 
cell percentage calculated by IF after 5h of culture. LoVo cell line shows the highest Caspase-3 percentage 
when co-cultured with LS174T. Each IF was repeated 4 times and 4 fields were counted in each slide. ± SEM 
is indicated.  
 
 
As showed in the CCA graph (Figure 2.5 A), the growth units of the line expressing less 
cMYC are lower in co-culture than those of the same cell line in separate conditions, and 
this is associated with a higher percentage of positive Cas-3 cells (figure 2.5 B).  
These results obtained in cell lines coming from different tumours confirm that cMYC can 
play a role in driving competitive interaction between different cancer cells. 
To assess if cMYC downregulation in the winner cell line was sufficient to lose the 
competitive drive, I performed a CCA on the LS174T and LoVo cell line pairs (figure 2.6) 
following cMYC chemical inhibition in the winner LS174T line, while the LoVo loser cell 
line was used in native conditions.  
Following chemical inhibition, cMYC protein levels were assessed by western blot (WB) 
in treated LS174T and mocked LoVo. As can be seen in Figure S.I. 2, cMYC inhibition 
induced a drastic decrease in cMYC levels in the treated LS174T line (lane 2), that were 
not rescued at the native levels (lane 4) also 5 hours after inhibition (lane 3). 
 
(A) (B) 
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Figure 2.6: CCA on LoVo and LS174Ti colon cancer cell lines. Co-cultured cell lines, indicated with cc, 
represent the first two bars of each graph; separated cell lines, indicated with sep, are the second two bars of 
each graph. A) Growth after 5h of culture; each assay was repeated 4 times and counted twice. B) Apoptotic 
cell percentage calculated by IF after 5h of culture. LS174Ti (treated with the inhibitor 10058:F4) shows the 
highest Caspase-3 percentage when co-cultured with native LoVo Each IF was repeated 4 times and 4 fields 
were counted in each slide. ± SEM is indicated.  
 
 
This CCA showed how cMYC inhibition in the LS174T cell line was sufficient to confer a 
competitive drive to the natively loser LoVo cell line. In fact, co-cultured LT174Ti 
displayed lower growth units than in separate conditions and the highest percentage of 
Cas-3 positive cells.  
This was clear demonstration that, whatever the genetic distance of two cell populations 
inhabiting the same field, cMYC modulation is sufficient to change their competitive 
status, suggesting a role for MMCC in the selective growth of early diverged clones and, 
as a consequence, in cancer evolution. 
 
2.4.  An in Vitro Model to Study MMCC in Genetically Identical Cells 
The IHC investigation revealed the presence of clones, within the carcinoma mass, 
characterised by different cMYC expression but sharing some molecular features  (HUGL-
1 delocalisation and YAP nuclear accumulation). This finding may be ascribable to a 
phenomenon of late genetic drift within the tumour. In a tumour mass composed of sibling 
cells, some local event may indeed trigger a sudden cMYC up-regulation. In this scenario, 
MMCC could play a role in the selection of the fittest clones.  
In order to evaluate whether differences in MYC levels were sufficient to drive 
competitive interactions in siblings from the same cancer cell line, I performed CCAs co-
culturing native cells and cells from the same line in which cMYC-MAX activity was 
previously inhibited by the same drug as in the previous assays. All the cell lines used in 
(A) (B) 
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the assays have been previously characterised for the expression of cMYC protein and 
cMYC target genes before and after the chemical treatment (figure S.I. 3 A and B). 
CCAs were performed on the same carcinoma cell lines as in the previous assays: lung 




Figure 2.7: CCA on H460 lung cancer cell lines. Co-cultured cell lines, indicated with cc, represent the first 
two bars of each graph; separated cell lines, indicated with sep, are the second two bars of each graph. A) 
Growth after 5h of culture; each assay was repeated 4 times and counted twice. B) Apoptotic cell percentage 
calculated by IF after 5h of culture. H460i (treated with the inhibitor 10058:F4) shows the highest Caspase-3 
percentage when co-cultured with mock-treated H460. Each IF was repeated 4 times and 4 fields were 
counted in each slide. ± SEM is indicated.  
 
In this CCA, after 5h of co-culture (fig 2.7 A) the H460 cells treated with the 10058:F4 
inhibitor (blue bar) show a significant decrease in growth compared to that of the same cell 
population plated in separate conditions (blue striped bar); its decrease is associated with a 
higher percentage of Cas-3 positive cells (fig 2.7 B, blue bar). Simultaneously, the native 
H460 cell population in co-culture (fig 2.7 A, red bar) exhibits a significative overgrowth 
compared to its competitor and shows an increased growth if compared to the H460 
population plated in separate conditions (red striped bar). Moreover, no significant increase 
in Cas-3 positive cells was found. Notably, the two cell populations in separate conditions 
show a similar growth (fig. 2.7 A, red striped and blue striped bars) and a similar Cas-3 
positive cell percentage (fig. 2.7 B, red striped and blue striped bars).  
This evidence suggests that the inhibition of MYC-MAX activity in the H460 cell line 
lowered its fitness and made it undergo apoptotic death as a consequence of the co-
presence of the H460 fitter cells. 
(A) (B) 
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Similar results have been obtained from the CCA performed on H1975 (figure 2.8 A- B), 
LS174T (figure 2.9 A- B) and LoVo (figure 2.10 A- B) cell lines.  
 
 
Figure 2.8: CCA on H1975 lung cancer cell lines. Co-cultured cell lines, indicated with cc, represent the first 
two bars of each graph; separated cell lines, indicated with sep, are the second two bars of each graph. A) 
Growth after 5h of culture; each assay was repeated 3 times and counted twice. B) Apoptotic cell percentage 
calculated by IF after 5h of culture. H1975i (treated with the inhibitor 10058:F4) shows the highest Caspase-
3 percentage when co-cultured with mock-treated H1975. Each IF was repeated 4 times and 4 fields were 




Figure 2.9: CCA on LS174T colon cancer cell lines. Co-cultured cell lines, indicated with cc, represent the 
first two bars of each graph; separated cell lines, indicated with sep, are the second two bars of each graph. 
A) Growth after 5h of culture; each assay was repeated 3 times and counted twice. B) Apoptotic cell 
percentage calculated by IF after 5h of culture. LS174Ti (treated with the inhibitor 10058:F4) shows the 
highest Caspase-3 percentage when co-cultured with mock-treated LS174T. Each IF was repeated 4 times 







	  	   64	  
 
 
Figure 2.10: CCA on LoVo colon cancer cell lines. Co-cultured cell lines, indicated with cc, represent the 
first two bars of each graph; separated cell lines, indicated with sep, are the second two bars of each graph. 
A) Growth after 5h of culture; each assay was repeated 3 times and counted twice. B) Apoptotic cell 
percentage calculated by IF after 5h of culture. LoVoi (treated with the inhibitor 10058:F4) shows the highest 
Caspase-3 percentage when co-cultured with mock-treated LoVo. Each IF was repeated 4 times and 4 fields 
were counted in each slide. ± SEM is indicated.  
 
 
During the early stages of cancer development, given the strong selective pressure imposed 
by the microenvironment, cancer clones can acquire different mutations and only a little 
proportion of mutant cells, that are not stalled or aborted, are able to initiate a malignant 
growth. 
According to the model of clonal evolution, starting from a cell within a new lesion, the 
accumulation of mutations gives rise to several phenotypically and genotypically divergent 
clones until a local new pressure wave or additional mutations occur that regulate the 
expansion of different clones by mutual competition, called clonal interference [7] [16] 
[28].    
Our results obtained in vitro suggest that either genetically distant or identical cancer 
clones may compete each other following sudden changes in cMYC expression. This 
phenomenon may represent a selective interference within tumour bulks, able to drive 
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2.5. An in Vivo Model to study MMCC in Cancer 
The data collected from the CCAs performed in cell culture let us hypothesise that, 
whatever the mutational burden of a cell population and whatever its fitness, Myc 
inhibition weakens its overall performance while sharing its living space with Myc-
expressing neighbours.  
That’s all the functional information we can get from an in vitro assay, but many issues 
remain unaddressed: what happens to cancer cells if they start to up- or down-regulate Myc 
while embedded in an expanding tumour? And what happens to neighbours? Do local 
competitive interactions have an impact at a distance or is their effect just sensed in a 
restricted area? What is the impact of MMCC on the overall tumour size?  
To answer these evolutive questions, I carried out an in vivo assay that allowed induction 
of Myc up- or down-regulating clones within a tumour mass growing in the animal and 




The image on the right is a section of an epithelial tumour growing within the l(2)gl4 
mutant larva. As described in the Introduction, in fact, the lgl LOF mutation in a 
homotypic background triggers loss of A/B cell polarity and uncontrolled proliferation (see 
the wild-type organ on the left for a comparison).  
Epithelial tumours induced by the LOF of neoplastic TSGs in Drosophila are known to 
show altered metabolism, dedifferentiation and upregulation of cytokine-like ligands, 
which drive tumour overgrowth [192]. In addition, several oncoproteins as Myc, dpERK 
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and pAKT are found overexpressed in theses organs, together with JNK-dependent 
expression of MMPs, nuclear accumulation of the Hpo pathway downstream effector Yki 
with its target dIAP1, and stabilisation of the HIF1α Drosophila homologue Sima in 
response to oxygen shortage [14]. Overall tissue architecture is compromised and cancer 
cells/clones undergo massive molecular and morphological separation. Despite lgl 
mutation is ubiquitous in the animal, each cell seems indeed to develop different 
disregulation patterns within the growing masses [14] and possibly different genetic and 
epigenetic alterations emerge that, as it happens in mammalian cancers, shape cancer 
evolution through sub-clone competition and interference [16] [28]  
lgl zygotes lacking maternal contribution die as embryos; maternal supply is hence 
sufficient to sustain the earliest stages of development [193] since Lgl is a highly stable 
protein[194]. Several cell cycles are indeed required before Lgl is completely depleted 
from the cell and its LOF phenotypes become evident; as a consequence, lgl mutant discs 
are not frankly malignant until 5 days from egg laying, despite they are composed at this 
stage of about one-third of the cells found in a wild-type disc [52]. Larval development 
lasts in the mutant larvae for additional 5-7 days, with late individuals showing huge 
masses that completely fill their anterior half.  
In this context, I induced l(2)gl4 (neutral), l(2)gl4, UAS-HAdm (mycOVER) or l(2)gl4, UAS-
dmRNAi (mycKD) clones at different stages of cancer progression and analysed, later in 
development, the phenotypic consequences of clone induction.. 
 
 2.5.1. Induction of MMCC in Genetically Distant Cells: the 6+2 Scheme  
With the aim to study how the emergence of MMCC in a late stage of cancer growth can 
shape both cell behaviour and overall tumour mass, I induced neutral, mycOVER and mycKD 
clones in an lgl LOF background at day 6, at a stage in which the wing imaginal discs 
show obvious neoplastic growth, and collect target tissues after two additional days of 
development (see In Vivo Materials and Methods for details). At day 8, GFP-positive 
larvae were selected under a fluorescence microscope, discarding those bearing large 
clones in the fat bodies, as it is known that Myc modulation in those tissues modifies 
organismal growth through the release of insulin-like peptides by the brain IPCs [195]. 
After having captured disc image with a dedicated camera to calculate disc volume, I 
dissociated them and counted GFP-positive and GFP-negative cells. As can be appreciated 
in Figure 2.11, GFP-positive cell percentage was much higher in the mycOVER sample than 
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in the neutral control (35,44% compared to 20,31%) and, contrarywise, it was 
significatively decreased in the mycKD sample (8,35% compared to 20,31%). 
 
                           
Figure 2.11: Percentage of GFP-positive (Green) and GFP-negative (Grey) cells from 8 days-old lgl, lgl 
mycOVER and lgl mycKD dissociated wing discs. Each assay was repeated 3 times and counted twice. ± SEM is 
indicated.  
 
This result showed that Myc clonal upregulation in a tumour context is sufficient to drive 
expansion of the Myc-overexpressing population and that, on the contrary, Myc 
downregulation in cancer cells restrains their proliferation.    
But what about the final tumour mass? I calculated the volume of each disc approximating 
its shape to a prolate spheroid, whose volume can be obtained by the formula: 4/3πa2b.                                                                       
As can be seen in Figure 2.12, while at day 6, before clone induction, the masses of the 
three samples were comparable in size, after two additional days of growth they appeared 
amazingly different: the average size of the mycOVER sample displayed an about 2.5 fold 
increase with respect to that of the neutral sample and, contrarywise, tumour mass 
appeared reduced to one-half in the mycKD sample. 
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Figure 2.12: Masses of lgl, lgl mycOVER and lgl mycKD cancer tissues before (6 days, lower areas) and after (8 
days, upper areas) clone induction. Each assay was repeated 3 times and counted twice. ± SEM is indicated.  
 
This was convincing evidence that both up- and downregulation of Myc during cancer 
progression can help shape cancer evolution and, as a consequence, final size. 
  
With the aim to analyse the contribution of the GFP-positive and the GFP-negative cells to 
the masses grown after clone induction (that is from day 6 to day 8), I calculated the 
average volumes of lgl, lgl mycOVER and lgl mycKD cells (see In Vivo Materials and 
Methods for details):  
lgl cells: GFP+ = 0.752 px3; GFP- = 0.752 px3  
lgl mycOVER cells: GFP+ = 0.989 px3; GFP- = 0.8 px3 
lgl mycKD cells: GFP+ = 0.518 px3; GFP- = 0.62 px3 
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Figure 2.13: Relative masses occupied by the GFP+ (Green) and the GFP- (Grey) cells in lgl, lgl mycOVER and 
lgl mycKD cancer tissues grown after clone induction. ± SEM is indicated.  
 
 
Of note, as can be observed in Figure 2.13, both GFP+ and GFP- populations expanded in 
lgl mycOVER tumours with respect to the neutral lgl masses and, on the other hand, both 
GFP+ and GFP- populations collapsed in lgl mycKD samples. The GFP+ MycOVER/neutral 
mass ratio was 6.75 and the GFP- MycOVER/neutral mass ratio was 2.53, while the GFP+ 
MycKD/neutral mass ratio was 0.057 and the GFP- MycKD/neutral mass ratio was 0.19. 
Let’s take a closer look to these numbers. In both MycOVER and MycKD samples, the major 
contribution to mass increase/decrease is due to the GFP+ population, demonstrating a 
genuine autonomous role of Myc modulation on cell growth and proliferation. The 
evidence that the untouched populations follow the same trend of the manipulated 
populations let us hypothesise that MycOVER and MycKD cells prime some non-autonomous 
phenomena which in turn amplify/constrain overall growth.  
 
I thus performed IF assays for Myc and Cas3 proteins, with the aim to investigate what 
happens at the interface between the GFP+ and the GFP- cells during cancer expansion. 
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In Figure 2.14 a tumourous organ is represented in which neutral, lgl clones have been 
induced. Independently of the GFP signal, we can observe several cell clusters in which 
Myc staining is lower compared to the surrounding cells, that result positive to Cas3 signal 
(arrows). This means that MMCC may be regularly at work in these masses.  
In the successive Figure (2.15) I show a closer view of a similar phenomenon: cells 
expressing very low levels of Myc (dotted line) surrounded by cells with high Myc 
expression are committed to die, as it is confirmed by a strong Cas3 staining. 
 
       
Figure 2.14: GFP+ neutral clones induced in an l(2)gl4 mutant background. Myc staining is in red and Cas3 
staining is in cyan. The arrows indicate cells with low Myc protein positive to a-Cas3 antibody. 
Magnification is 400X.	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Figure 2.15: GFP+ neutral clones induced in an l(2)gl4 mutant background. Myc staining is in red and Cas3 
staining is in cyan. The dotted line encircles a Cas3-positive area showing low Myc levels with respect to the 
neighbouring cells. Magnification is 800X.	  
 
These data suggest that MMCC is normally at work in these tumours, and it shapes cancer 
evolution through the elimination of the less fit cells (with lower levels of Myc protein) 
allowing the expansion of the most performant ones (with higher levels of Myc protein). 
Concerning MMCC, these cancers seem thus to recapitulate what happens in physiological 
conditions during Drosophila  [93] [109] and mammalian [136] [137] development, but 
growth is not allometric in cancer and final size may be surprising. 
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Figure 2.16: GFP+ lgl mycOVER clones induced in an l(2)gl4 mutant background. Myc staining is in red and 
Cas3 staining is in cyan. The arrows indicate GFP-, Cas3-positive areas showing lower Myc levels with 
respect to the neighbouring cells. Magnification is 400X. 
 
 
A partial answer came from the IF carried out on mycOVER samples. As can be seen in 
Figure 2.16, several cell groups with low Myc levels encircled by or adjacent to GFP-
positive cells with high Myc expression show strong Cas3 signal (arrows indicate some). 
This demonstrates that, through clonal induction of Myc, we are enhancing the same 
mechanism as in the previous experiment: in this case, cells catching an “overdose” of 
Myc respond showing super-competitive behaviour in the tissue. 
Figure 2.17 focuses closely on the same phenomenon: GFP-negative cells (marked by a 
dotted line) surrounded by high GFP-positive, high Myc-expressing neighbours succumb, 
losing the battle for space occupancy within the growing mass.  
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Figure 2.17: GFP+ lgl mycOVER clones induced in an l(2)gl4 mutant background. Myc staining is in red and 
Cas3 staining is in cyan. The dotted lines indicate GFP-, Cas3-positive areas showing lower Myc levels with 
respect to the neighbouring cells. Magnification is 800X. 
 
 
Another interesting observation concerns the fact that I found very few mycOVER cells 
dying within the sample I examined: this sounded unusual, as Myc ectopic expression is 
known to induce massive autonomous cell death in the fruit fly [126]; it is however known 
that, also in mammals, normal cells respond to high Myc levels by undergoing apoptosis, 
whereas tumour cells resist the apoptotic effects of Myc [196]. The cells in which I 
induced Myc upregulation have definitely passed multiple rounds of apoptosis, and 
survivors are somehow “addicted” to Myc: an overdose of this protein can thus be 
redirected to boost growth, proliferation and competitive drive.  
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In addition, those cells show deregulation of the Hpo pathway with nuclear accumulation 
of the anti-apoptotic protein dIAP1[14], which directly targets effector caspases in 
Drosophila [197]. 
Beside a huge expansion of the winner population, an increase of the GFP-negative mass 
was also noticed (Figure 2.13); a possible explanation for this observation is that some 
signalling molecules are secreted by both losers and winners, such as cytokine-like ligands, 
[192] that, catched by surrounding competent cells, may help amplify the original signals 
and contribute to the overall growth of the tumour. 
 
           
Figure 2.18: GFP+ lgl mycKD clones induced in an l(2)gl4 mutant background. Myc staining is in red and 
Cas3 staining is in cyan. The arrows lines indicate GFP+, Cas3-positive cells showing low Myc levels with 
respect to the neighbouring cells. Magnification is 400X. 
 
Opposite results have been obtained following induction of mycKD clones in the growing 
cancers. As can be observed in Figure 2.18, discs are smaller with respect to both neutral 
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and mycOVER samples (Figg. 2.14 and 2.16) and express low levels of Myc protein. This 
restriction in organ size had already been observed by mass calculation (Figure 2.12) and, 
as for the previous sample, GFP-negative cells seem to follow the same trend of the GFP-
positive population; in this case, native cells are under-represented with respect to the 
control sample (Figure 2.13).  
 
 
Figure 2.19: GFP+ lgl mycKD clones induced in an l(2)gl4 mutant background. Myc staining is in red and 
Cas3 staining is in cyan. The arrows lines indicate GFP+, Cas3-positive cells showing low Myc levels with 
respect to the neighbouring cells. The arrowheads point to native GFP-, Cas3-positive cells showing low Myc 
levels with respect to the neighbouring cells. Magnification is 800X. 
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In Figure 2.19 a closer view is presented in which a myriad of GFP-positive, mycKD cells 
undergo PCD. In addition, arrowheads indicate some native, Myc-downregulating cells 
that are out-competed by neighbouring Myc-positive cells.  
Possibly, the introduction of a number of losers (mycKD) in the system triggers a 
“relaxation” of the original MMCC: the native cells expressing low levels of Myc are now 
able to outcompete the newcomers as lower Myc levels are sufficient to win the 
competition in this context. The stressful metabolic cost of the winners can thus be limited, 
inducing cells to slow down their overall growth and proliferation rates. 
 
2.5.2. Induction of MMCC in Genetically Related Cells: the 2+6 Scheme  
After having observed what happens following induction of neutral, mycOVER and mycKD 
clones at a stage in which the wing imaginal disc is frankly malignant, we were interested 
in carrying out the same experiments as above in an epithelial organ well before the onset 
of cancer. As specified above, lgl mutant epithelia do not show any signs of neoplasia until 
the Lgl protein is completely depleted, that is 5 days from egg deposition. I thus induced 
the mutant clones at 2 days from egg laying and let larvae develop for additional 6 days 
before dissection and analysis. Cell count was performed as in the previous scheme and the 
results are illustrated in Figure 2.20. 
                   
Figure 2.20: Percentage of GFP-positive (Green) and GFP-negative (Grey) cells from 8 (2+6) days-old lgl, 
lgl mycOVER and lgl mycKD dissociated wing discs. Each assay was repeated 3 times and counted twice. ± 
SEM is indicated.  
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As can be appreciated in the figure, I was able to find very few GFP-positive cells 
compared to the previous scheme, although the relative numbers gave similar information: 
the GFP-positive cells in the mycOVER sample were about 2-fold those found in the neutral 
sample and the mycKD masses contained about 1/10 GFP+ cells with respect to the neutral 
masses. This was convincing evidence that, whatever the stage at which Myc deregulation 
occurs in a developing mass, its increase supports autonomous growth and its reduction is 
detrimental for the cell. 
 
                         
Figure 2.21: Masses of lgl, lgl mycOVER and lgl mycKD cancer tissues at 6 days from clone induction. Each 
assay was repeated 3 times and counted twice. ± SEM is indicated.  
 
A surprising result came from mass calculation: while mycKD samples were comparable in 
size to the neutral controls, mycOVER tumours showed enormous growth, with the final 
mass more than threefold the control one. As this did not correlate with a GFP-positive 
huge number, some questions have to be addressed before drawing opportune conclusions. 
In principle, clone induction has similar efficiency when heat pulse duration, temperature 
and other experimental conditions are similar; this implies that a comparable percentage of 
cells undergoes Flippase-mediated excision in the target tissue. Being the 2-days lgl wing 
disc composed of about one-hundred cells, it it plausible that very few are modified by our 
manipulation, and this explains why the mycKD sample was comparable in size to the 
neutral one: the few mycKD cells induced at the very beginning of development are 
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immediately out-competed by the sorrounding epithelium and the tumour follows its native 
course.  
It is more difficult to find a convincing reason for the behaviour of the mycOVER tumours: 
the few mutant cells induced at the beginning of disc development may justify the scarce 
percentage of GFP-positive cells found in this sample, but this does not account for the 
huge non-autonomous mass overgrowth. It is possible that local MMCC provokes a wave 
of pro-growth signals across the expanding mass and that competent cells are able to 
amplify these signals, but it is also possible that the GFP construct got lost because of 
genomic instability happened in these masses. It is indeed demonstrated that some tumours 
show genomic instability in Drosophila [198], but it doesn’t not seems to be associated 


















	  	   79	  
Chapter 2 
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The premise of the study  
Lgl/HUGL-1 is a protein involved in the maintenance of the A/B cell polarity; cells mutant 
for lgl/HUGL-1 loosen each other contacts, grow in 3D and the epithelium shows deep 
alterations in its overall architecture [52]. Loss of cell polarity induces, in turn, inactivation 
of the Hpo pathway, Yki/YAP nuclear accumulation and transcription of many 
proliferative and anti-apoptotic targets, included dMyc/MYC [130][134]. Cells 
overexpressing MYC can, in some contexts, trigger competitive interactions and expand at 
the expense of the normal surrounding tissue, eliminated by apoptotic death. 
p53 is one of the most frequently mutated genes in human cancers and the function of its 
several mutant products and dominant negative forms is not clear. 
A very recent work focused the attention on a fundamental role for p53 in MMCC in 
Drosophila, according to which the presence of the wild-type p53 protein in Myc over-
expressing cells is required to gain a winner status and out-compete the neighbours [168].  
Our IHC analysis showed that some essential traits of CC in Drosophila [52][130][66] are 
conserved in a large collection of samples from primary and secondary human carcinomas.  
In addition to this, our in vitro experiments defined a role for cMYC in driving the winner 
fate during competitive interactions in human cancer cells lines, and its down-regulation 
was found to be sufficient to revert the phenomenon.   
Finally, our in vivo investigations demonstrated how MMCC is involved in shaping the 
final tumour mass and in selecting the fittest cells in Drosophila epithelial tumourigenesis. 
 
 The Aim of the study  
This part of the study aims at characterising the role of p53 in MMCC using cellular and 
animal cancer models in which p53 function will be opportunely modulated. 
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2.6. MMCC in Human Carcinomas Seems to be Associated with p53 Protein Status 
Although the most part of the primary and secondary carcinomas analysed by IHC showed 
evident signs of MMCC (Fig 2.1), clear evidence was missing in some samples. In the 
view of the very recent work by the Johnston’s group [168]. I decided to correlate the 
status of p53, evaluated through an antibody that recognises both the wild-type and the 



































Figure 2.22: IHC on several human carcinomas: (A) MYC (pink) and Cleaved Cas-3 (brown). (B) p53 
(pink) I-. lung adenocarcinoma (A) signs of CC: cancer cells show high levels of c-MYC protein surrounded 
by stromal cells with high staining for Cleaved Caspase-3; (B) p53 staining shows high accumulation of the 
protein in the nucleus of cancer cells (200X). II- ductal breast carcinoma. (A) signs of CC  (B) presence of 
p53 with no massive nuclear accumulation (100X). III- colon adenocarcinoma (A) no evident signs of CC, 
(B) absence of p53 staining, (200X). The arrows point towards the dying cells. 
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The following expected scenario was found: in human samples where markers of MMCC 
were found (fig. 2.22 IA and IIB, black arrows indicate Cas-3 positive cells) p53 nuclear 
staining was evident (fig 2.22 IIA and IIB), while in samples where the Cas-3 signal 
resulted absent in the stroma surrounding the cMYC-expressing mass (fig. 2.22 III- A), 
p53 staining was negative. 
This qualitative analysis led us to perform in vitro CCAs to study p53 implication in 
mammalian MMCC. 
 
2.7. The Winner Status of Cancer Cells Requires p53 Function   
To experimentally evaluate the involvement of the wild-type p53 function in MMCC in 
cancer, I performed the same CCAs as in Part 1 using two cell lines from the same human 
colorectal carcinoma: HCT116 (hereafter called HCT116wt) and HCT116p53-/-. 
The HCT116p53-/- cell line was established by targeted homologous recombination by Bunz 
and colleagues from the parental colorectal carcinoma HCT116wt line [200].  
The two cell populations are genetically identical, except for the p53 mutation: HCT11p53-/- 
harbours the p53 exon 3 deletion, resulting in an inactive form of the protein unable to be 
revealed by the p53 antibody Do-1; cMYC protein levels were comparable in the two cell 
lines  (fig. S.I. 5). 
I performed the first CCA between the HCT116wt and the HCT116wt treated with the 
10058:F4 inhibitor (fig. 2.23) to evaluate whether differences in cMYC may activate 
competitive behaviours also in this cell population. Preliminary characterisation of the cell 
lines used in this part of the work, before and after treatment with the drug 10058:F4, has 
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Figure 2.23: CCA on HCT116wt and HCT116wti colon cancer cell lines. Co-cultured cell lines, indicated 
with cc, represent the first two bars of each graph; separated cell lines, indicated with sep, are the second two 
bars of each graph. A) Growth after 5h of culture; each assay was repeated 3 times and counted twice. B) 
Apoptotic cell percentage calculated by IF after 5h of culture. HCT116wti (treated with the inhibitor 
10058:F4) shows the highest Caspase-3 percentage when co-cultured with mock-treated HCT116wt. Each IF 
was repeated 4 times and 4 fields were counted in each slide. ± SEM is indicated.  
  
 
As can be noted in Figure 2.23 A, after 5 hours of CCA the two cell lines show different 
growth rates in co-culture and in separate conditions: the HCT116wt in a native condition 
(red bar) overgrow compared to the HCT116wti (blue bar), whereas the two cell 
populations show similar growth rates in separate conditions (red striped and blue striped 
bar). The growth disadvantage of the treated cell population in co-culture is associated with 
the highest Cas-3 positive signal (fig. 2.23 B, blue bar). 
These data show that MMCC can be induced in this cell line. 
With the aim to evaluate if p53 protein played a role in loser cells during MMCC, I 
performed a CCA between the HCT116wt and the HCT116p53-/- treated with the inhibitor 
















Figure 2.24: CCA on HCT116wt and HCT116p53-/-i colon cancer cell lines. Co-cultured cell lines, indicated 
with cc, represent the first two bars of each graph; separated cell lines, indicated with sep, are the second two 
bars of each graph. A) Growth after 5h of culture; each assay was repeated 4 times and counted twice. B) 
Apoptotic cell percentage calculated by IF after 5h of culture. HCT116p53-/-i (treated with the inhibitor 
10058:F4) shows the highest Caspase-3 percentage when co-cultured with mock-treated HCT116wt. Each IF 
was repeated 4 times and 4 fields were counted in each slide. ± SEM is indicated.  
 
The assay showed similar results as those from the previous one, as the HCT116wt and 
HCT116p53-/-i in co-culture exhibited the typical competitive behaviour according to the 
growth units (fig. 2.24 A) and the profile of Cas-3 staining (fig 2.24 B). The result of this 
experiment, associated with a CCA performed using two other cancer cell lines, H460 and 
H1299 (fig. S.I. 7), in which the first line has higher expression level of cMYC protein 
than the H1299, which harbor an homozygous partial deletion of the p53 protein (fig. S.I. 
8), strongly indicated that p53 LOF in loser cells does not affect MMCC both in 
genetically distant and identical cancer cell lines.   
Finally, to verify whether p53 wild-type protein is required in the winner cells to induce 
MMCC, I performed a CCA between HCT116p53-/- and HCT116wtI cell lines, where the 









	  	   86	  
 
 
Figure 2.25: CCA on HCT116p53-/- and HCT116wti colon cancer cell lines. Co-cultured cell lines, indicated 
with cc, represent the first two bars of each graph; separated cell lines, indicated with sep, are the second two 
bars of each graph. A) Growth after 5h of culture; each assay was repeated 4 times and counted twice. B) 
Apoptotic cell percentage calculated by IF after 5h of culture. Each IF was repeated 4 times and 4 fields were 
counted in each slide. ± SEM is indicated.  
 
The graph shown in Figure 2.25(A) illustrates how the potential winner cell line does not 
show differences in growth units compared to the potential loser population, defining the 
absence of competitive interactions, coherent with the hypothesis that p53 is required in 
MYC-overexpressing cells to drive CC. No significative variations emerged in 
proliferative units between co-culture and separate conditions.  
Moreover, as can be seen in Figure 2.25 (B), the percentage of Cleaved-Caspase 3 positive 
cells is coherent with the CC assay count: none of the cell lines showed an increase in 
apoptosis in co-culture.  
Further confirmation of this behaviour was achieved through a CCA assessed between the 
HCT116p53-/- and HCT116p53-/-i lines (fig. 2.26 A and B ): it can be seen that competition 
does not occur between the p53 KO lines even if a strong difference in cMYC protein 














Figure 2.26: CCA on HCT116p53-/- and HCT116p53-/-i colon cancer cell lines. Co-cultured cell lines, indicated 
with cc, represent the first two bars of each graph; separated cell lines, indicated with sep, are the second two 
bars of each graph. A) Growth after 5h of culture; each assay was repeated 3 times and counted twice. B) 
Apoptotic cell percentage calculated by IF after 5h of culture. Each IF was repeated 4 times and 4 fields were 
counted in each slide. ± SEM is indicated.  
 
The two cell populations in co-culture showed a similar growth (fig. 2.26 A, red and blue 
bars) lower than that observed in separate conditions ( fig. 2.26 A, striped bars), and their 
Cas-3 positive cells (fig. 2.26 B, red and blue bars) are coherently slightly higher than in 
separate conditions (fig. 2.26 B, striped bars). 
The results of these experiments confirmed the hypothesis that a p53 wild-type function is 
required also in humans for MMCC to occur. The effect is not organ-specific as the same 
results have been obtained using the lung cancer line H1299 (fig. S.I. 9), whose its MYC- 
MAX activity has previously been inhibited (fig. S.I. 10) 
 
2.8. Differences in p53 Status do not Drive CC in Cancer Cells 
Noteworthy, a different status of p53 is not sufficient to induce MMCC in HCT116 cancer 
cell lines. 
This evidence was obtained from a CCA where the HCT116wt and the  HCT116p53-/- cell 
































Figure 2.27: CCA on HCT116wt and HCT116p53-/- colon cancer cell lines. Co-cultured cell lines, indicated 
with cc, represent the first two bars of each graph; separated cell lines, indicated with sep, are the second two 
bars of each graph. A) Growth after 5h of culture; each assay was repeated 4 times and counted twice. B) 
Apoptotic cell percentage calculated by IF after 5h of culture. Each IF was repeated 4 times and 4 fields were 
counted in each slide. ± SEM is indicated.  
 
 
The growth units graph (fig. 2.27) does not show any competitive interactions at work as 
the two cell lines in co-culture (fig. 2.27 A, red and blue bars) exhibit similar proliferative 
rates. This seems to be a typical growth profile of populations where competitive 
interactions are relaxed (see fig 2.27).  
Their apoptotic death (fig. 2.27 B, red and blue bars) appear to be higher than cells grown 
in separate wells, maybe as a result of the stress induced by the co-presence.  
Altogether, these results demonstrate that p53 function is necessary downstream of MYC 
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2.9.  Back to Drosophila: in Vivo CCA in a Cooperative Model of Carcinogenesis 
de la Cova and colleagues demonstrated that p53 wild-type function is required in Myc-
overexpressing cells to successfully out-compete the neighbours and overgrow during 
normal development [168], but evidence is still missing about a similar role of p53 in 
MMCC during cancer growth. 
After having performed the CCA in human cancer cell lines and having collected plenty of 
data about a possible role of p53 in MMCC in vitro, we wanted to confirm this evidence in 
vivo.  
I carried out a series of experiments with the aim to investigate the contribution of p53 to 
MMCC as a specific trait of carcinogenesis. I took advantage of a cooperative cancer 
model that uses the l(2)gl4 tumour suppressor mutation induced in a clonal fashion together 
with the over-expression of Myc (Mycover); the cooperation between lgl LOF and Myc 
GOF is indeed known to trigger competitive overgrowth in the wing disc [141].  
Through the use of the MARCM system (see Materials and Methods) I induced the 
following clones: 
- lgl mutation (l(2)gl4) together with Myc overexpression (Mycover); 
- lgl mutation (l(2)gl4) together with Myc overexpression (Mycover) and p53KD (an RNAi 
construct that decreased the p53 transcript to about 50% at 25°C, mimicking a 
heterozygous condition, (fig. S.I. 11);  
- lgl mutation (l(2)gl4) together with Myc overexpression (Mycover) and p53DN (used as a 
p53 LOF [201]); 
As can be seen in Figure 2.28, l(2)gl4, Mycover clones are able to overgrow in any region of 
the disc. Of note, these mutant clones often appear to merge and many GFP-positive cells 
are found scattered throughout the wing pouch, a clear sign of migration (see Fig. 2.28 A) 
attributable to the malignant nature of these cells, as Drosophila normal or hyperplastic 
clones grow compact, with daughter cells remaining side by side (141). This feature seems 
to be rescued in both l(2)gl4, Mycover, p53KD and l(2)gl4, Mycover, p53DN clones (Fig. 2.28 
B- C). 
	  	   90	  
 
Figure 2.28:	   	  Imaginal wing discs from l(2)gl4, Mycover (A), l(2)gl4, Mycover, p53KD (B) and l(2)gl4, Mycover, 
p53DN (C) L3 larvae. GFP+ clones are black (0XLgl) and twin clones are intense red (2XLgl), while the 
background is red (1XLgl). The dotted line encircles the wing pouch region of the discs. 	  
 
To support this morphological evidence, I carried out a measurement of the clonal mutant 
areas in the wing pouch region (encircled by dotted lines in Figure 2.17) whose results are 
illustrated in figures 2.18- 2.20. 
The statistical analysis performed on l(2)gl4, Mycover, p53KD clones showed that average 
clone area is reduced to about 50% (fig. 2.30) respect to that of the l(2)gl4, Mycover clones 
(Figure 2.29), and to about 25% in l(2)gl4, Mycover, p53DN clones (Figure 2.31). 
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Figure 2.29:	   	  Average clonal area of l(2)gl4, Mycover clones (blue) and wild-type twins (grey). For each 





Figure 2.30:	   	  Average clonal area of l(2)gl4, Mycover, p53KD clones (blue) and wild-type twins (grey). For 
each sample, 20 clones in different wing discs have been measured at 200X magnification. Error bars 
represent the SEM. 	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Figure 2.31:	   	  Average clonal area of l(2)gl4, Mycover, p53DN  clones (blue) and wild-type twins (grey). For 
each sample, 20 clones in different wing discs have been measured at 200X magnification. Error bars 
represent the SEM.  
 
These results suggest that p53 partial/complete LOF is able to restrict both clonal 
expansion and malignancy of l(2)gl4, Mycover cells in the wing disc. This cell-autonomous 
growth restriction is a counterintuitive evidence, as heterozygous/homozygous p53 loss is 
known to support growth and malignancy in a variety of biological systems [202]. The 
oncogenic side of p53 has just begun to be investigated, but it is possible that in this 
particular trait of tumourigenesis, that is MMCC, p53 loss perturbs the metabolic status of 
the Mycover cells thus decreasing their neoplastic potential.  
Further to show the cell-autonomous role of p53 in tumourigenesis, my analysis on clonal 
areas highlighted an interesting non-autonomous trait of the phenomenon we are 
investigating.   
As can be seen in Figure 2.32, the wild-type twins of the l(2)gl4, Mycover, p53KD clones are 
not statistically different from the wild-type twins of the l(2)gl4, Mycover clones. This means 
that a partial loss of p53 is able to rescue growth and malignancy of the l(2)gl4, Mycover 
cells, but it does not seem to affect their competitive properties.  
On the contrary, the wild-type twins of the l(2)gl4, Mycover, p53DN clones are statistically 
greater with respect to both others. Being the twins of all the mutant clones composed of 
genetically identical cells (wild-type), this statistical difference is obviously due to the 
different genotypes of the neighbour mutant clones, showing that complete removal of p53 
severely impairs l(2)gl4, Mycover cells’ competitive drive. 
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Taken together, these data seem to indicate that clonal expansion and competitive ability 
are separable traits of cancer. Further analysis is however necessary to confirm and 




Figure 2.32:	  	  Average clonal area of the wild-type twins of l(2)gl4, Mycover (left bar); l(2)gl4, Mycover, p53KD 
(central bar) and l(2)gl4, Mycover, p53DN (right bar) clones. For each sample, 20 clones in different wing discs 
have been measured at 200X magnification. Error bars represent the SEM.  
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Cancer is a heterogeneous and complex disease, with cells showing distant phenotypes as a 
result of dynamic changes in their genome. 
 
Its extraordinary variety led researchers to arrange a taxonomic organisation where quasi-
classes, genera and species characterised by divergent cells of origin make every cancer 
individually unique.  
Cancer evolves by continuous processes of clonal expansion, genetic diversification and 
clonal selection within tissue ecosystems. Therapeutic intervention may decimate cancer 
clones and disrupt their habitats, but it provides unavoidably a potent selective pressure for 
the expansion of resistant variants.  
To understand cancer genetic dynamics it is important to recognise it as a population in 
constant crosstalk with its surrounding environment. Thus cancer has to be viewed and 
analysed as an evolving ecosystem where cells are in constant communication and 
interaction with their environment. Populations, in order to use more and more resources to 
survive and proliferate, can elaborate strategies of ecological interactions listed as positive, 
as commensalism, synergism and mutualism, and negative as predation, parasitism, 
amensalism and competition, where one population is inhibited or eliminated by another 
one that gains advantages in space and resources.  
 
The work I presented demonstrates that MYC-Mediated Cell Competition (MMCC) is at 
work during cancer progression, and this phenomenon seems to represent a central 
mechanism necessary for cancer clone selection and tumour mass expansion. 
 
My investigation revealed typical signs of MMCC in human carcinomas, not only between 
cancer cells and the surrounding stromal tissue but, surprisingly, clear signs were also 
found within tumour cells, making us speculate that CC is used by the tumour mass to kill 
neighbours and gain a bigger amount of available resources and space, but also to select for 
the fittest clones amid cancer sub-populations. In this context, MMCC and its selective 
weapon, the MYC protein, represent a clear example of clonal interference aimed at 
gaining even more resistant behaviours.  
 
I then developed an in vitro clone competition assay to demonstrate that MMCC is able to 
shape clone evolution in different contexts. I co-cultured pairs of genetically distant cell 
lines (to mimic MMCC between early diverged cancer clones) and genetically identical 
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cell lines (to mimic MMCC between late diverged cancer clones) and the results I obtained 
confirmed that MYC protein modulation is per se sufficient to subvert their competitive 
behaviours. 
 
At this point, in order to find some answers to the evolutive questions related to MMCC, I 
chose to find a way to define the contribution of MMCC to tumour evolution in vivo, and I 
decided to develop a clone evolution assay in Drosophila. 
 
I used lgl LOF mutant animals, known to undergo loss of apical-basal cell polarity and 
uncontrolled proliferation of the epithelial tissues, that show altered metabolism, 
dedifferentiation, upregulation of cytokine-like molecules and many other malignant 
features, described along the main text. In this lgl LOF background, I induced neutral, 
mycOVER and mycKD clones at different stages of cancer progression, and precisely at six 
days of development, a stage in which the wing imaginal disc shows obvious neoplastic 
growth, and at two days of development, when lgl mutant epithelia are still phenoypically 
normal. Target tissues were collected at eight days of development. 
 
The first, interesting observation was that MMCC is normally at work in these tumours 
through the continuous elimination of the less fit cells (with lower levels of Myc protein), 
allowing the expansion of the strongest (with higher levels of Myc protein) (paragraph 
2.5.). 
The induction of Myc over-expressing clones conferred cells a super-competitive 
behaviour, enhancing the overall competitive interactions within the tumour mass and, as a 
result, tumours overgrew (fig 2.13). As the growth of the tissue was also contributed by the 
native population (fig 2.13), although to a lesser extent than the mycOVER cells, this was 
clear demonstration that cancers behave like a cell community in which growth signals are 
systemically released and sensed, eventually generating an important expansion of the 
tumour bulk if compared to controls (fig 2.12). 
On the other hand, the final size of the masses in which I induced mycKD clones resulted 
significantly reduced, and also in this case both mycKD and native cells contributed to the 
mass collapse, consistent with a signal of collective relaxation.  
 
These were both important and amazing results, as they seem to suggest that while MMCC 
acts in a leading role in shaping the tumour mass as a consequence of mechanisms of 
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positive and negative pressure, the tumour cells at a distance from the happening are 
however able to detect that selective pressure and gain higher Myc expression to survive, 
thus acting in supportive roles: “when the going gets tough the tough get going”. 
 
In addition, my study defined the presence of a functional cooperation between MYC and 
p53 in MMCC in cancer, as p53 LOF in the winner cells make them unable to grow and 
out-compete the neighbours. 
p53 is one of the most frequently mutated genes in human cancers and the function of its 
several mutant products and dominant negative forms is not clear. As its tumour suppressor 
functions are well-known, many efforts are being made by the scientific community to 
reactivate its function in cancer.  
But if p53 wild-type protein is also necessary to Myc-expressing cells to grow and out-
compete neighbours during cancer progression, an oncogenic side of wild-type p53 should 
also be considered. 
Given this dual role of p53, a better characterisation of all its functions and its mutated 
forms seems to urge in order to evaluate its actual role in cancer history. 
 
Altogether, my results showed that MMCC plays an active role in the selective pressure we 
observed during cancer growth, favouring the most performant cells within the tumour and 
opposing to the expansion of the weakest derivatives. This evidence represents an 
important step towards the understanding of the evolutionary mechanisms underlying 
tumourigenesis. 
 


























	  	   101	  
    Chapter 4 
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4.1. Ex Vivo and In Vitro Materials and Methods - Parts 1 and 2 
 
Immunohistochemistry (IHC) 
Immunohistochemical staining for c-MYC (mouse monoclonal 9E10; DSHB; 1:50), YAP-
1 (rabbit polyclonal, Cell Signaling, 1:150)), HUGL-1 (by courtesy of Dennis Strand, 
rabbit polyclonal, 1:550) and Cleaved Caspase-3 (rabbit polyclonal, #9961 Cell Signaling, 
1:250) was carried out on 5 µm thickness FFPE (formalin-fixed paraffin-embedded) 
histological sections of several types of human epithelial  primary and secondary tumour 
samples (see tab. 1).  
The whole set of sequential slides was first heat-deparaffinised (30 min at 65°C), 
rehydrated and antigen retrieval has been carried out with citric acid pH 8 at 95oC for 30 
minutes. 
The stainings for YAP-1 and HUGL-1 were performed on separate slices using Thermo 
Scientific, UltraVision kit and each specific HRP-secondary antibody was revealed using 
DAB+ reaction. 
The staining for c-MYC and Cleaved-Caspase-3 were performed on the same section using 
Dako EnVision G/2 Doublestain System kit, Rabbit/Mouse (DAB + / Permanent Red) 
which allows a double antigen hybridisation in the same slide through specific primary 
antibody recognition by HRP  (Horseradish peroxidase enzyme), and A/P (Alkaline 
phosphatase enzyme)- conjugated polymer secondary systems. 
All primary antibodies were incubated at 4°C overnight, and all secondary HRP/AP-
conjugated polymers at room temperature for 10 minutes. 
Slides were counterstained with Hematoxylin (nuclear dye), dehydrated, mounted and 
analysed. IHC for p53 (mouse monoclonal, DO-1, abCAM) has been carried out using the 
“Automatic Ventana BenchMark XT” Immunoistochemistry System. 
For cancer and stroma identification, all the samples were analysed by an expert 
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Primary Mass Secondary Lesions 
Ductal carcinoma in situ (DCIS)- Left breast  Lymph Node Metastasis 
Lobular carcinoma in situ (LCIS)- Right breast Lymph Node Metastasis 
Mucinous Cystadenocarcinoma- Left breast Lymph Node Metastasis 
Ductal invasive G3 carcinomas- Left breast Lymph Node Metastasis 
Ductal invasive G2 carcinomas- Left breast Lymph Node Metastasis 
Infiltrating papillary thyroid carcinoma Lymph Node Metastasis 
Lung adenocarcinoma (NSCLC)- Left lobe Brain Metastasis 
Lung poorly differentiated carcinoma (NSCLC)- Left lobe Brain Metastasis 
Lung squamous cell carcinoma (SCC)- Left lobe Brain Metastasis 
Pleomorphic adenoma of the cheek Brain Metastasis   
Oesophageal carcinoma  Brain Metastasis 
Colorectal Adenocarcinoma Liver Metastasis 
Colorectal Adenocarcinoma Liver Metastasis 
Colorectal Adenocarcinoma                               Liver Metastasis 
Endometrial carcinoma Colorectal Metastasis 
 




Human Carcinoma cell lines (see tab. 2) from ATCC were cultured in DMEM-containing 
10% heat-inactivated FBS (fetal bovine serum), 2mM of glutamine and 1% antibiotics 
(100 U/ml of Penicillin/ 100 µg/ml of Streptomycin) in 5% CO2 humidified air atmosphere 
at 37°C. 
Cell lines Cancer Type: Notes: 
 
















Homozygous partial deletion of 
the p53 protein. 
 






















p53 exon 3 deletion [203]. 
 
Table 4.2: Human carcinoma cell lines used in this study and their characteristics. 
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Cell Count 
Cell were washed in PBS 1X, detached with trypsin 1X, collected in DMEM medium, 
pelleted by centrifugation and suspended in DMEM 10% FBS complete medium. Count 
and viability were quantified by cell counting with Trypan Blue exclusion using the 
Bürker’s chamber applying the following equation: 
[(Average n° of Trypan blue negative cells in 9 squares · 104) · Dil. Factor] · ml of cell 
suspension, obtaining the total number of viable cells suspended in the initial volume. 
 
10058:F4 Treatment 
The MYC-MAX small molecule inhibitor 10058:F4 (Sigma-Aldrich) was used to reduce 
MYC-MAX activity [204] through its binding to the MYC bHLHZip dimerisation domain. 
MYC-MAX small molecule inhibitor 10058:F4 was dissolved in dimethyl- sulphoxide 
(DMSO). 
To assess the inhibitory effect of the drug, cells were seeded in a 6-well plate at a density 
of 5x105 cells per well and allowed to settle for 24 hours at 5% CO2 humidified air 
atmosphere at 37°C, before starting the treatment. 10058:F4 (and an equivalent amount of 
DMSO for controls) was applied at different concentrations with fresh medium.  
After 24 hours of treatment, cells were washed in PBS 1X, detached with trypsin 1X, 
collected in DMEM and treated for RNA isolation for following qRT-PCR (to assess 
transcripts variations) or treated for total protein extraction for Western Blot analysis.  
In CCAs, the 10058:F4 inhibitor was used at a concentration of 60µM as lower 
concentrations did not show significant effects on MYC-MAX activity and higher 
concentrations induced autonomous cell death.  
Cells for CCAs (see further) were plated as before, where under treatment cells were plated 
with 60µM of 10058:F4 and non-treated cells were incubated with an equivalent amount of 
DMSO. After 24 hours at 5% CO2 humidified air atmosphere at 37°C, cells were washed 
in PBS 1X, detached with trypsin 1X, collected in DMEM, counted and used for the 
assays. 
 
PKH67 (Sigma-Aldrich) Cell Membrane Labelling 
PKH67 is a fluorescent cell membrane dye characterised by a long aliphatic carbon tail 
than binds the phospholipid bilayers of the cell membrane, while its fluorogenic moiety is 
exposed near the outer surface of the cell. It is widely used to for in vitro and in vivo cell 
tracking. This tracker is characterised by no cytotoxic effects and reduced cell-cell transfer.   
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PKH67 was used to label one of the two populations used in the CCAs (see further) 
according to the manufacture’s bulletin: cells were gently detached with trypsin 1X and 
washed twice with minimum DMEM medium, as serum interferes with labelling 
efficiency. Cells were counted with trypan blue exclusion method and 5/7x106cells were 
used for the staining. Simultaneously, PKH67 was mixed with 2 ml of Diluent C solution 
to obtain a 10µM staining solution, then applied to the cell pellet and incubated for 5 
minutes at room temperature. The reaction was then blocked with an equal volume of FBS 
for 1 minute at room temperature, as the serum competes for the aliphatic carbon tail 
binding to the cell membrane. Stained cells were centrifuged for 10 minutes at 400g, 
complete DMEM was added and cell viability and fluorescent intensity were assessed.  
To exclude side effects of PKH67 on CCAs, a test on two different cell lines was 
performed in which the two cell populations were alternatively stained, and no differences 
in the final results were appreciable between the two conditions. 
 
Cell Competition Assays (CCAs) 
To experimentally evaluate the phenomenon of MMCC in human carcinoma cell lines, a 
cell-based assay was designed and performed. 
Each assay was carried out by using two different human carcinoma cell populations 
characterised by different cMYC expression levels or two sub-populations from the same 
cell line in which one was previously treated with the MYC-MAX 10058:F4 inhibitor. The 
cell lines used in each CCA showed comparable proliferation rates.  
One of the two populations forming the assay was previously labelled with the aim to 
distinguish the two cell lines during and after the assay.  
The cell lines were counted with the Trypan blue exclusion method and, in a 6-wells plate, 
2,5x105 cells from each line were plated in co-culture; simultaneously, 5x105 cells from 
each population were plated in separate conditions, both in standard growth and medium 
conditions. After 5 hours incubation, the wells were gently washed in PBS 1X, cells were 
detached with trypsin 1X, collected and counts were assessed in a Bürker’s chamber using 
a wide-field fluorescence microscope. The number of cells obtained after 5 hours 
incubation has been normalised to the number of the cells plated at the beginning, 
obtaining the growth units for each cell line in the different conditions. Cell competition 
outcome was evaluated after 5 hours of co-culture according to literature’s information 
[95].  As a control, we however performed some cell counts also after 12 and 24 hours, but 
we were not able to find significative changes in the final results. Each experiment has 
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been performed at least 3 times independently and each single count was repeated twice. 
Data were statistically analysed using GraphPad Prism®
 
free software.   
  
Immunofluorescence (IF) on CCAs   
IF assays were performed to verify the apoptotic rate of the cells during the CCAs, by 
using a specific antibody directed against the active form of the Caspase 3 (Cleaved-
Caspase 3), as loser cell elimination is Caspase 3 dependent in Drosophila [98] [93] [205] 
and in mammals [206]. 
A cover slip previously washed in EtOH 100% was settled on the bottom of every well of a 
6-wells plate coated with collagen 50ng/µl in glacial acetic acid 0,02N and incubated for 1 
hour at room temperature under a laminar flow hood. The excess collagen was aspirated, 
plates were washed twice in PBS 1X and cells were seeded as previously described.  
After 5 hours growth, cells were gently washed in PBS 1X and fixed with 
Paraformaldehyde 2% (PFA) for 15 minutes at room temperature and rinsed 3 times with 
PBS-T (PBS 1X + Triton 0,1%) for 5 minutes. Cells were incubated for 30 minutes with 
Normal Donkey Serum 4% (NDS) diluted in PBS-T. Finally, Cleaved Caspase-3 antibody 
(rabbit polyclonal, 9961; Cell Signaling; 1:250) in PBT/NDS 4% was incubated overnight 
at 4°C. The secondary anti-rabbit antibody, (AlexaFluor™ 555, Invitrogen; 1:300) in 
PBT/NDS 4% was incubated for 1 hour at room temperature. A solution containing DAPI 
2µg/ml PBS1X was used in the final wash to counterstain cell nuclei. The coverslips were 
mounted using Fluoromount™ glycerol-mounting medium (Sigma- Aldrich) and visualised 
under a wide-field fluorescence microscope. Four fields were counted in each slide; each 





Total Protein Extraction, SDS PAGE and Western Blotting 
Sub-confluent cells from a 100mm dish were washed in PBS 1X, detached with Trypsin 
1X, collected in DMEM, centrifuged and lysed in RIPA buffer added with protease 
inhibitors (Complete, Roche; PMSF, Sigma-Aldrich) for 15 minutes at 4°C. Following 
chemical lysis, sonication was carried out to increase the detergent effect of RIPA buffer 
and break chromatin aggregates. After centrifugation, the supernatant containing the total 
protein extract was collected and quantification was carried out using the BCA protein 
method (Pierce™ BCA Protein Assay Kit). 
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50µg lysate were mixed with Laemmli Loading buffer 4X and denatured for 10 minutes at 
100°C. Samples were resolved on 4/10% acrylamide/bisacrylamide gel for 90 minutes, 
120Volt at room temperature. After migration, proteins were transferred to a nitrocellulose 
membrane in which immuonodetection is successively carried out. The transfer reaction 
was performed at constant amperage (300mA) for 1 hour and 45 minutes at 4°C in Tris-
Glycine/Methanol based transfer buffer. Blocking in 4% Milk solution has been applied for 
1 hour at room temperature to the membrane before incubation with the primary antibodies 
overnight at 4°C. Primary antibodies used were: anti-c-MYC (Rabbit, Santa Cruz, N-262; 
1:1500), anti-p53 (Do-1, mouse, AbCAM; 1:1000) and anti-β-Actin (Rabbit, Jackson 
ImmunoResearch; 1:2000). The HRP-conjugated secondary antibodies used were goat anti-
rabbit and anti-mouse (Jackson ImmunoResearch 1:2000) for 1 hour at room temperature.  
The HRP-ECL reaction has been revealed using Bio-Rad Chemidoc™.  
 
Ripa buffer 1X Running buffer 1X Transfer buffer 1X Blocking solution 
50mM TrisHCl pH7.5 10% Tris- Glycine  5% Tris- Glycine  20mM TrisHCl pH8 
150mM NaCl  0.1% SDS  20% Methanol   20mM NaCl  
0.5%  Na Deoxycholato   mqH2O mqH2O 25gr Powder milk  
1% NP40    0.05% Tween20  
0.1% SDS    mqH2O 
1mM PMSF     
1X Complete (Roche)     
mqH2O    
4X Laemmli buffer 10% Running gel 4% Stacking gel  
250mM TrisHCl pH6.8 10% Acry/ bisacryl  4% Acry/ bisacryl   
40% Glycerol  300mM TrisHCl pH8.8 150mM TrisHCl pH6.6  
5% SDS  0.1% SDS  0.1% SDS   
0.005% Bromoph. Blue  0.1% APS  0.1% APS   
mqH2O 0.05% TEMED  0.05% TEMED   
 mqH2O mqH2O  
 
Table 4.3: Western blot Solutions  
 
RNA Extraction and Purification, RT-PCR, Sybr Green qPCR  
 
Cells from 100mm dishes were directly scraped in TRI-Reagent® (Sigma-Aldrich) and 
processed or stored at -80°C before being processed. 
The larvae were obtained from a culture of 5 days after egg  laying. About 15 larvae were 
homogenised in a vial with TRI Reagent® (Sigma- Aldrich), centrifuged for 5 minutes at 
12000g at 4°C and the supernatant was collected to be processed. 
300µl of chloroform were added to the samples containing 1ml of TRI Reagent® (Sigma- 
Aldrich) solution and vortexed for 10 seconds. The samples were incubated for 10 minutes 
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at room temperature and centrifuged for 12 minutes at 12000g at 4°C. The RNA-
containing aqueous phase was transferred to a new tube, where 750µl of isopropyl alcohol 
were added. Samples were mixed gently, incubated 10 minutes at room temperature and 
centrifuged for 12 minutes at 12000g at 4°C. The supernatant was removed, the pellet was 
washed three times with 1 ml 75% EtOH and centrifuged at 7500g for 5 minutes at 4°C. 
The supernatant was removed and the dried pellet was eluted at 55°C for 10 minutes in 
50µl of mqH2O. A DNAse I-treatment followed to avoid genomic contamination.  
 
cDNA synthesis was performed using total DNA free-RNA with oligo(dT) in a 0,2ml tube, 
and using the ThermoScript™ RT-PCR system. The ThermoScript is an engineered avian 
reverse transcriptase with reduced RNase H activity that shows high thermal stability and 
produces high amounts of full-length cDNAs. Each mix is prepared as follows: 1µg di 
RNA + 2X RT Reaction Mix (oligo dT 2,5µM, random examers 2,5 ng/µl, MgCl2 10 mM, 
dNTPs) + RT enzyme Mix (Retrotranscriptase e RNase OUT) + mqH2O up to the final 
volume.  
 
SYBR GreenER qPCR SuperMix (Invitrogen) is a ready-to-use cocktail containing all 
components, except primers and template, for real-time quantitative PCR (qPCR) on 
ICycler BioRad real time instruments that support normalisation with Fluorescein 
Reference Dye at a final concentration of 500nM. It combines a chemically modified 
“hotstart” version of TaqDNA polymerase. SYBR GreenER qPCR SuperMix is supplied at 
a 2X concentration and contains hot-start TaqDNA polymerase, SYBR GreenER 
fluorescent dye, 1 µM Fluorescein Reference Dye, MgCl2, dNTPs and stabilisers. The 
SuperMix formulation is compatible with melting curve analysis. 
The amplification is based on 40 cycles x 3 steps: after 3 minutes denaturation at 95oC, 
each amplification step includes: 30 second at 95oC (denaturation), 15 seconds at 60oC 
(annealing temperature for each primer pair), 30 seconds at 72oC (elongation step). The 
resulting graph is the relative quantity of the target gene transcript compared to the 
transcript quantity of the reference gene. For each sample, an amplification curve is shown 
in a Cartesian graph: the x axis represents the cycle number and the y axis represents the 
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Table 4.4: Real Time PCR primers used and main features. c-MYC: Homo sapiens v-myc avian 
myelocytomatosis viral oncogene homologue ; BRCA1: Homo sapiens Breast cancer 1; BRCA2: Homo 
sapiens Breast cancer 2; GUSB: Homo sapiens Glucuronidase, beta (reference gene); GAPDH: Homo 
sapiens glyceraldehyde-3-phosphate dehydrogenase (reference gene); dMyc: Drosophila melanogaster Myc 
oncogene; dMax: Drosophila melanogaster Max; Dmp53: Drosophila melanogaster p53; GFP: Green 
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Statistics 
For CCAs, all values are the mean of at least 3 independent experiments where each single 
count was repeated twice; for IF, the percentage of Casp-3 positive cells are the mean of 4 
fields counted for each experiment. Student’s t test was performed to determine 
significance (two-tailed, unequal variance). p values are as follows:  p≤0.05=*, p≤0.01=**, 
p≤0.001=***. All error bars are ± standard error of the mean (SEM), if not differently 
indicated. All data were statistically analysed using GraphPad Prism® version 5.01 for 
windows, GraphPad Software, San Diego California USA: www.graphpad.com	  
 
4.2. In Vivo Materials and Methods  
	  
Drosophila melanogaster has been used as animal model and the experiments were 
performed in a larval organ that is widely used for CC assays: the wing imaginal disc.  
The original lines and the crosses were reared at 25°C on a medium composed of water, 
agar, glucose, baker yeast, cornmeal in the right proportions. A chemical is finally added to 
prevent moulds.  
Mutant and transgenic lines described have been obtained, if not otherwise specified, from 
the Bloomington Drosophila Stock Center, Indiana. For information about mutations, 
transgenes and enhancers please see: http://flystocks.bio.indiana.edu/	  
	  
Drosophila Model Tissue: The Imaginal Wing Disc 
Imaginal discs are larval epithelial organs that give rise to adult structures and appendages.  
The imaginal wing disc, precursor of the adult wing, is composed of a pseudostratified 
columnar epithelium of undifferentiated and proliferating cells that represent the actual 
imaginal disc, and by a squamous epithelium that forms the peripodial membrane (Fig.4.1 
A ). The first will originate the integument and the wing, the second will originate the 
epithelial veil that welds the structures [207]. 
When it is formed during embryonic development, the wing imaginal disc comprises 
around 20 cells [207]. These cells intensely proliferate during the second and third larval 
instars to generate a disc of around 50,000 cells in the late third instar (96h after hatching). 
By this stage, the wing primordium is established and its major elements can be identified.  
The centrifugal regions will originate the dorsal and ventral body wall thorax structures: 
notum and pleura. The middle region will give rise to the hinge, while the central region, 
the wing pouch, is the presumptive territory from which the wing lamina differentiates. 
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(Fig.4.1 B, [207]) For this reason, the wing pouch is defined as the distal region of the 
wing disc while hinge and pleura are considered as proximal. 
The wing imaginal disc represents an excellent model widely used to study growth and 
proliferation control in epithelial tissues. It is morphologically and biochemically very 
similar to mammalian epithelia and it encounters a dramatic increase in cell number in a 
relatively short length of time with an average cycle time of 8.5h [208]. 	  
	  
Figure 4.1 . A): A third instar imaginal wing disc. The presumptive regions that correspond to the adult wing 
structures (shown in b) are labelled. Dorsal and ventral wing surfaces compose the wing pouch. A cross 
section of the epithelium and the peripodial membrane is also shown on the right. B) Adult wing. the 
different structures are coloured according to the presumptive territories they originate from (shown in A). 
Longitudinal veins (L 1-5), anterior (A) and posterior (P) compartments are also indicated. Adapted from 
[207].	  
 
4.2.1. Drosophila Methods Used in Part 1	  
Mutations	  
lgl4 (lethal giant larvae)  recessive lethal mutation of the lgl gene caused by a spontaneous 
loss of the subtelomeric 21A2 region; 	  
y67c23 (yellow)  X-associated recessive mutation: the body is yellow and the mouth 
apparatus of the larva is brown;  
w1118 (white)  X-associated recessive mutation: the eye is white because of a complete lack 
of pigmentation; 
Bc (Black cells) II-associated dominant mutation: the larval crystal cells are substituted by 
melanotic masses;  
Cy (Curly)  II-associated dominant mutation; wings are curled upward; 
Gla (Glazed) II-associated dominant mutation: the eye is reduced and misshaped and 
ommatidia appear fused. 
Hu (Humeral)   III-associated dominant mutation; alteration of humeral bristles number; 
Tb (Tubby)  III-associated dominant mutation; shorter and thicker larvae, pupae and adults. 
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Balancer Chromosomes 
In(2LR)GlaBc  II chromosome carrying multiple arrangements associated with Gla and Bc 
dominant markers, recessive lethal; 
In(2LR)O (CyO - Curly of Oster) II chromosome carrying multiple arrangements 
associated with Cy dominant marker, recessive lethal; 
In(2LR)SM5  II chromosome carrying multiple arrangements associated with Cy dominant 
marker, recessive lethal; 
In(3LR)TM6b  II chromosome carrying multiple arrangements associated with Hu and Tb 
dominant markers, recessive lethal. 
 
Transgenes  
hs-Flp  X-associated construct encoding the yeast recombinase Flippase under the control 
of a heat-shock promoter; 
act5c>CD2>Gal4 III-associated Flp-out construct driven by actin5c gene promoter, 
bearing CD2 cDNA between FRT sequences (>) (Paola Bellosta); 
UAS-GFP  III-associated construct encoding a nuclear GFP protein downstream of a UAS 
enhancer; 
UAS-HAdmyc  III-associated construct encoding the fly Myc protein with a HA epitope 
downstream of a UAS enhancer (Paola Bellosta); 
UAS-dmRNAi  II-associated construct encoding an interfering RNA specific for the dm 
transcript downstream of a UAS enhancer (VDRC 2847); this construct knocks down the 
dm transcript of about 50% (Figure S.I. 12), mimicking a heterozygous condition.  
 
Flp-out system [209] 
The Flp-Out technique allows clonal expression of UAS constructs combining the UAS-
Gal4 system with Flp-FRT mediated recombination. A Flp-Out construct consists in a 
constitutive promoter (in this case, actin5c) followed by an FRT cassette, a sequence 
encoding a cell marker with a polyA terminator (in this case, CDC2), a second FRT 
cassette and a Gal4 sequence. When activated, Flippase expression can induce excision of 
the DNA sequence comprised between the two FRT sites placed in the same orientation. 
Following this, the constitutive promoter can thus transcribe the Gal4 sequences that will, 
in turn, drive the expression of all the UAS-transgenes present in the line, including a 
visible cell marker (in this case, UAS-GFPnls) to allow clone identification. 
 
	  	   114	  
Lines and Crosses: 
Driver line: 
yw, hs-Flp; l(2)gl4/CyO; act5c>CD2>Gal4, UAS-GFPnls/TM6b 
Responder lines: 
1. w; l(2)gl4/SM5 
2. w; l(2)gl4, UAS-dmRNAi/SM5 
3. w; l(2)gl4/In(2LR)GlaBc; UAS-HAdm 
 
Larvae of interest: 
1. yw, hsFlp/w; l(2)gl4/l(2)gl4; act5c>CD2>Gal4, UAS-GFPnls/+ 
2. yw, hsFlp/w; l(2)gl4/l(2)gl4, UAS-dmRNAi; act5c>CD2>Gal4, UAS-GFPnls/+ 
3.  yw, hsFlp/w; l(2)gl4/l(2)gl4; UAS-HAdm,/act5c>CD2>Gal4, UAS-GFPnls 
 
In those larvae, I induced l(2)gl4 neutral clones (1), l(2)gl4 MycKD clones (2) or l(2)gl4 
MycOVER clones (3) at different stages of cancer development, as follows: 
 
Myc Deregulation in Genetically Distant Cells: 6+2 Scheme 
 
 





144±4h larvae grown at 25°C were heat-shocked for 2 
minutes at 37°C in an eppendorf immersed in a water 
bath. After the heat-shock, larvae were transferred to 
fresh food and allowed to grow for additional 2 days at 
25°C. Finally, wing discs were collected from GFP+ 
larvae for successive analyses. 
	  
48±4h larvae grown at 25°C were heat-shocked for 8 
minutes at 37°C in a food vial immersed in a water 
bath. After the heat-shock, vials were immersed in 
fresh water for 5 minutes, then transferred for 
additional 6 days at 25°C. Finally, wing discs were 
collected from GFP+ larvae for successive analyses. 
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Mass calculation 
144±4h and 192±4h larvae were dissected at 4°C in PBS1X (Phosphate Buffer Saline, pH 
7.5) under a stereoscope, imaginal wing discs were isolated from the carcasses and 
transferred in clean PBS1X. A picture of the discs collected each day was captured at 25X 
using a dedicated digital camera. Disc areas in pixel2 were measured using ImageJ 
Software from NIH and areas were transformed in volumes following the same formula as 
for prolate spheroids: 4/3 π a2b. 
 
Cell volume calculation 
Sequential Z stacks were taken under a confocal microscope for each 6+2 sample stained 
for the membrane marker aPKC (Santa Cruz, 1:200) and the cell area of all the GFP+ and 
GFP- cells included in 4 different fields were measured using ImageJ Software by NIH. 
Cell volume has been calculated by approximating cell shape to a sphere.  
 
Dissociation and Cell count 
Wing discs collected each day were washed twice in PBS1X and incubated with gentle 
agitation for 2.5 hr in 1 ml PBT (4.5 mg/ml porcine trypsin-EDTA [Sigma-Aldrich] in 
PBS1X). Cell count was carried out using the Bürker’s chamber applying the following 
equation: [(Average n° cells in 9 squares · 104) · Dil. Factor] · ml of cell suspension, 
obtaining the total number of cells suspended in the initial volume. 
 
Statistics 
All values are the mean of at least 3 independent experiments where each single count was 
repeated twice. The number of wing discs analysed was 30÷90 for each sample. p values 
are as follows:  p≤0.05=*, p≤0.01=**, p≤0.001=***. All error bars are ± standard error of 
the mean (SEM), if not differently indicated. All data were statistically analysed using 




192±4h larvae from the 6+2 scheme were dissected in PBS1X (Phosphate Buffer Saline, 
pH 7.5), fixed in 3,7% formaldehyde (Sigma) diluted in PBS1X and permeabilised in PBT 
0,3% for 90 minutes. They were then incubated with the primary antibody solution 
(PBT/BSA 2%) overnight at 4oC. The next day the carcasses were washed and incubated 
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for 2 hours at room temperature with a mix of the secondary antibodies. Finally, wing 
imaginal discs were isolated under a stereoscope and mounted in FluoromountG (Beckman 
Coulter). Samples were analysed with Leica TSC SP2 laser confocal microscope and entire 
images were processed with Adobe Photoshop software. All the images shown represent a 
single confocal stack. Primary antibodies: anti-cleaved Cas3 (rabbit polyclonal, #9961; 
Cell Signaling; 1:100) and anti-Myc (mouse, P. Bellosta, 1:5). Secondary antibodies: 555 
Alexa Fluor anti-mouse 1:200 and Cy5 DyLight Jackson Laboratories anti-rabbit 1:500. 
 
4.1.2. Drosophila Methods Used in Part 2	  
Mutations	  
lgl4 (lethal giant larvae)  recessive lethal mutation of the lgl gene caused by a spontaneous 
loss of the subtelomeric 21A2 region; 	  
y67c23(yellow)  X-associated recessive mutation: the body is yellow and the mouth 
apparatus of the larva is brown;  
w1118 (white)  X-associated recessive mutation: the eye is white because of a complete lack 
of pigmentation; 
Bc (Black cells) II-associated dominant mutation: the larval crystal cells are substituted by 
melanotic masses; 	  
Gla (Glazed) II-associated dominant mutation: the eye is reduced and misshaped and 
ommatidia appear fused. 
 
Balancer Chromosomes 
In(2LR) GlaBc, II chromosome carrying multiple arrangements associated with Gla and 
Bc dominant markers, recessive lethal. 
 
Transgenes  
hs-Flp  X-associated construct encoding the yeast recombinase Flippase under the control 
of a heat-shock promoter; 
tub-Gal4 X-associated construct encoding the yeast Gal4 protein under the control of the 
tubulin promoter; 
tub-Gal80  II-associated construct encoding the yeast Gal80 protein under the control of 
the tubulin promoter; 
UAS-lglRNAi III-associated construct encoding a double strand interfering RNA specific 
for the lgl transcript downstream of a UAS enhancer (VDRC 51249); 
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UAS-GFP  X-associated construct encoding a nuclear GFP protein downstream of a UAS 
enhancer; 
UAS-HAdmyc III-associated construct encoding the fly Myc protein with a HA epitope 
downstream of a UAS enhancer (Paola Bellosta); 
UAS-p53RNAi III-associated construct encoding a double strand interfering RNA specific 
for the p53 transcript downstream of a UAS enhancer (#41720); 
UAS-p53DN  III-associated construct encoding a dominant negative form of the fly p53 
protein downstream of a UAS enhancer (#8421). 
 
MARCM (Mosaic Analysis with a Repressible Cell Marker) (Lee and Luo 1999) 
In l(2)gl4 heterozygous individuals I induced the expression, by mitotic recombination, of 
homozygous l(2)gl4 clones bearing the UAS-HAdm and/or UAS-p53KD or UAS-p53DN 
constructs. The mosaic technique allowed to define the criteria of CC and the role of p53 in 
tumour growth. This has been reached by comparing the clonal areas of the GFP-positive 
mutant clones to those of the respective wild-type twin clones. The flippase enzyme, that 
gives rise to mitotic recombination, was activated by a heat-shock promoter, hence the 
larvae underwent 20 minutes heat-shock at 37oC 48±4 hours after egg laying. After 72 
hours, L3 larvae bearing GFP clones were dissected in PBS1X, fixed in formaldehyde 
3,7% and frozen in 70% ethanol in PBS 1X.  
 
The following crosses were carried out to perform this analysis: 
♀♀ yw,hs-Flp,tub-Gal4,UAS-GFP; tub-GAL80, FRT40A  (driver line) 
X 
1.      ♂♂ w; l(2)gl4, FRT40A/GlaBc; UAS-HAdm, UAS-lglKD  
An irrelevant (RNAi)lglKD construct was added to this cross to make Gal4 titration 
comparable in all the progenies and as a control of the RNAi machinery activation. 
2.   ♂♂ w; l(2)gl4, FRT40A/GlaBc; UAS-HAdm, UAS-p53KD 
3.   ♂♂ w; l(2)gl4, FRT40A/GlaBc; UAS-HAdm, UAS-p53DN   
Larvae of interest: 
1. yw,hsFlp,tubGal4,UAS-GFP/w; l(2)gl4, FRT 40A/ tubGal80,FRT40A;UAS-HAdm,UAS-lglKD /+ 
2. yw,hsFlp,tubGal4,UAS-GFP/w;l(2)gl4,FRT40A/tubGal80,FRT40A;UAS-HAdm,UAS-p53KD/+ 
3.  yw,hsFlp,tubGal4,UAS-GFP/w;l(2)gl4,FRT40A/tubGal80,FRT40A;UAS-HAdm,UAS-p53DN/+ 
Upon the heat shock, recombination occurs and mutant cells face while growing with wild-
type twin cells in which the recombination event has placed two copies of the tub-Gal80 
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repressor, so that they do not express GAL4 and the UAS-related products. By comparing 
the clonal areas of mutant and twin clones it was possible to evaluate both growth rate and 
competitive abilities of the mutant cells. The analysis was restricted to the wing pouch 
region so to make it more homogeneous and significant. The clonal areas were measured in 
pixel2 by using the ImageJ Software from NIH and normalised to the wing pouch total area 
so to bypass the differences in wing disc overall dimensions. A statistic analysis was 
performed whose parameters are reported in the figure legends. 
 
Immunofluorescence 
Larvae collected at the end of the larval life were used for the IF analysis using the anti-
Myc and anti-Lgl antibodies. Larvae were dissected in PBS1X (Phosphate Buffer Saline, 
pH 7.5) and fixed in 3,7% formaldehyde (Sigma) diluted in PBS1X. The larval carcasses 
collected each day, with the imaginal discs attached to the cuticle, were frozen after 
dehydration in a crescent alcoholic scale from 30% to 70% EtOH. Immediately before IF, 
the carcasses were rehydrated and permeabilised in PBT 0,3%  for about 40 minutes. They 
were then incubated with the primary antibody solution (PBT/BSA 2%) overnight at 4oC. 
The next day the carcasses were washed and incubated for 2 hours at room temperature 
with a mix of the secondary antibodies. Finally, wing imaginal discs were isolated under a 
stereoscope and mounted in FluoromountG (Beckman Coulter). The images for clonal area 
measurement were captured under a wide-field fluorescence Microscope (Nikon Eclipse 
90i) and measured using the ImageJ software from NIH. Samples were analysed with 
Leica TSC SP2 laser confocal microscope and entire images were processed with Adobe 
Photoshop software. All the images shown represent a single confocal stack. Primary 
antibodies: anti-Lgl (rabbit, D. Strand, 1:400) and anti-Myc (mouse, P. Bellosta, 1:5). 
Secondary antibodies: 555 Alexa Fluor anti-rabbit 1:500 and Cy5 DyLight Jackson 











	  	   120	  
 
	  	   121	  
          
	  
Figure S.I. 1:  Comparison of cMYC protein expression in the cell lines used for CCAs. Western blot 








Figure S.I. 2: cMYC protein characterisation in LoVo and LS174T cell lines used in CCA before and after 
10058:F4 treatment. Total proteins for Western blot analysis were extracted after the LoVo (lane 1) and 
LS174T (lane 4) were mock-treated with DMSO for 24h; LS174T was treated with 60µM 10058:F4 for 24h 
(lane 2); the same treated cell line was recovered in complete medium for 5h post 10058:F4 treatment (lane 
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Figure S.I. 3: Characterisation of cell lines used in CCA before and after 10058:F4 treatment. Total Proteins 
for Western blot analysis and total RNAs for qReal Time PCR analysis were extracted after the cells were 
treated with DMSO for 24h (dmso lane); treated with 60µM 10058:F4 for 24h (10058:F4 24h lane) and were 
recovered in complete medium for 5h post 10058:F4 treatment (recovery 5h lane). (A.) Western blot analysis 
of cMYC and β-Act as normaliser in H460, H1975, LS174T and LoVo. (B.) qReal Time PCR in H460, 
H1975, LS174T and LoVo on c-MYC (dark grey bar), BRCA1 (grey bar), BRCA2 (light grey bar); GUSB was 


















































Figure S.I. 6: Characterisation of HCT116wt and HCT116p53-/- after 10058:F4 treatment. Total proteins for 
Western blot analysis and total RNAs for qReal Time PCR analysis were extracted after the cells were 
treated with DMSO for 24h (dmso lane); treated with 60µM 10058:F4 for 24h (10058:F4 24h lane) and 
recovered in complete medium for 5h post 10058:F4 treatment (recovery 5h lane) (A.) Western blot analysis 
on cMYC, and b-ACT as normalizer. (B.) qReal Time PCR on  c-MYC (dark grey bar), BRCA1 (grey bar), 
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Figure S.I. 7:  CCA between H1299 and H460. H460 wins the competition; H460 shows higher cMYC 
expression level and presence of p53 protein; H1299 exhibits a lower cMYC protein level than H460 and 
absence of p53. (A) H1299 shows the profile of a loser cell; growth after 5h of culture; each assay was 
repeated 3 times and counted twice. Its growth in co-culture is lower than H460 in the same condition and 
lower than the two populations in separate conditions. (B) Cas-3 profile confirms H1299 loser behaviour. 
Each IF was repeated 4 times and 4 fields of each slides were analysed, counted twice. ±SEM indicated. 


















Figure S.I. 8:  Western blot analysis on cMYC, p53 and β-Act as normaliser in H1299 and H460. H460 
show higher cMYC expression and presence of p53 protein; H1299 exhibits lower cMYc protein level than 
H460 and absence of p53. 
(A) (B) 
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Figure S.I.  9:  CCA between H1299 and H1299 treated with the 10058:F4 inhibitor. (A) H1299 and H1299i 
show similar growth when co-cultured (red and blue bar); their proliferation rate in co-culture is similar to 
that in separate conditions (striped red and striped blue bars). Growth after 5h of culture; each assay was 
repeated 4 times and counted twice. (B) Percentage of cells positive for cleaved caspase-3 is similar for co- 
cultured cell populations (red and blue bar) and cells in separate conditions (striped red and striped blue 
bars). No signs of CC are evident. Each IF was repeated 4 times and 4 fields of each slide were analysed, 
counted twice. ±SEM indicated. These data confirm that p53 wild-type function is needed in the potentially 




	  	  	  	  	  	  	  	  	  	  	   	  
 
Figure S.I. 10: Characterisation of H1299 after 10058:F4 treatment. Total Proteins for Western blot analysis 
and total RNAs for qReal Time PCR analysis were extracted after the cells were treated with DMSO for 24h 
(dmso lane); treated with 60µM 10058:F4 for 24h (10058:F4 24h lane) and were recovered in complete 
medium for 5h post 10058:F4 treatment (recovery 5h lane). (A.) Western blot analysis on cMYC and β-Act 
as normaliser (B.) qReal Time PCR on c-MYC (dark grey bar), BRCA1 (grey bar), BRCA2 (light grey bar);  


























Figure S.I. 11: Characterisation of dp53 RNA interference on dp53 gene transcript. The relative quantity of 
p53 mRNA was assessed by qReal Time PCR in L3 larvae bearing a p53 RNAi construct under the control of 
the act5c-Gal4 driver. mRNA from L3 larvae with a UAS-GFP cassette under the control of the same driver 








Figure S.I. 12: Characterisation of dmyc RNA interference constructs on chromosome II and III. The 
relative quantity of dmyc mRNA was assessed by qReal Time PCR in L2 (for the III chromosome construct) 
and L3 (for the II chromosome construct) larvae bearing different dmyc RNAi constructs under the control of 
the act5c-Gal4 driver. mRNA from L3 larvae with a UAS-GFP cassette under the control of the same driver 
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